PiHKAL: The Chemical Story 8
This is part 4 of 6 of the second half of PiHKAL: A Chemical Love Story, by Alexander Shulgin and Ann Shulgin. Please forgive any typos or misprints in this file; further, because of ASCII limitations, many of the typographical symbols in the original book could not be properly represented in these files.
If you are seriously interested in the chemistry contained in these files, you should order a copy of the book PiHKAL. The book may be purchased for $22.95 ($18.95 + $4.00 postage and handling) from Transform Press, Box 13675, Berkeley, CA 94701. California residents please add $1.38 State sales tax.
At the present time, restrictive laws are in force in the United States and it is very difficult for researchers to abide by the regulations which govern efforts to obtain legal approval to do work with these compounds in human beings.... No one who is lacking legal authorization should attempt the synthesis of any of the compounds described in these files, with the intent to give them to man. To do so is to risk legal action which might lead to the tragic ruination of a life. It should also be noted that any person anywhere who experiments on himself, or on another human being, with any of the drugs described herin, without being familiar with that drug's action and aware of the physical and/or mental disturbance or harm it might cause, is acting irresponsibly and immorally, whether or not he is doing so within the bounds of the law.
#90 IDNNA; 2,5-DIMETHOXY-N,N-DIMETHYL-4-IODOAMPHETAMINE
SYNTHESIS: To a stirred solution of 0.4 g 2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) in 12 mL MeOH containing 4 mL of a 40% formaldehyde solution there was added 1 g sodium cyanoborohydride. The pH was kept at about 6 by the occasional addition of HCl. When the pH was stable (about 48 h) the reaction mixture was poured into 250 mL H2O and made strongly basic by the addition of aqueous NaOH. This was extracted with 3x75 mL CH2Cl2, the extracts pooled, and extracted with 2x75 mL dilute H2SO4, and the pooled acidic extracts again made basic and again extracted with CH2Cl2. The solvent was removed under vacuum to give 0.38 g of a colorless oil. This was dissolved in 2 mL IPA and treated with a solution of 0.13 g oxalic acid dihydrate in 1.5 mL warm IPA, and then anhydrous Et2O was added dropwise until a turbidity persisted. Slowly a granular white solid appeared, which was filtered off, Et2O washed, and air dried to give 0.38 g of 2,5-dimethoxy-N,N-dimethyl-4-iodoamphetamine oxalate (IDNNA) with a mp of 145-146 °C. Anal. (C15H22INO6) C,H. The hydrochloride salt of this base proved to be hygroscopic.
DOSAGE: greater than 2.6 mg.
DURATION: unknown.
EXTENSIONS AND COMMENTARY: This base, if it were given a code name based upon its substituents arranged in their proper alphabetical order, would have to be called something like DNDIA, which is quite unpronounceable. But by a rearrangement of these terms, one can achieve IDNNA (Iodo-Dimethoxy-N,N-dimethyl-Amphetamine) which has a nice lilt to it.
One of the major goals of research in nuclear medicine is a drug that can be used to demonstrate the brain blood flow pattern. To do this job, a drug should demonstrate four properties. First, it must carry a radioactive isotope that is a positron emitter (best, a fluorine or an iodine atom, for use with the positron camera) that can be put onto the molecule quickly, synthetically, and which will stay on the molecule, metabolically. Second, as to brain entry, the drug should be rapidly and extensively taken up by brain tissue, without being selectively absorbed or concentrated at any specific sites. In other words, it should go where the blood goes. Thirdly, the absorption should be strong enough that it will stay in the brain, and not be washed out quickly. This allows time to both locate and count the radioactivity that was carried in there. And lastly, the drug must be without pharmacological action.
IDNNA looked like a promising candidate when tried with a radioactive iodine label, and there was quite a flurry of interest in using it both as an ex-perimental drug, and as a prototype material for the synthesis of structural variants. It went in quickly, extensively and quite diffusely, and it stayed in for a long time.
But was it pharmacologically active? Here one finds a tricky road to walk. The animal toxicity and behavioral properties can be determined in a straightforward manner. Inject increasing amounts into an experimental animal and observe him closely. IDNNA was quite inert. But, it is a very close analogue to the extremely potent psychedelic DOI, and it is widely admitted that animal assays are of no use in trying to determine this specific pharmacological property. So, a quiet human assay was called for. Since it did indeed go into the brain of experimental animals, it could quite likely go into the brain of man. In fact, that would be a needed property if the drug were to ever become useful as a diagnostic tool.
It was assayed up to levels where DOI would have been active, and no activity was found. So one could state that it had none of the psychedelic properties of DOI at levels where DOI would be active (this, at 2.6 milligrams orally). But you don't assay much higher, because sooner or later, something might indeed show up. So it can be honestly said, IDNNA is less active than DOI itself, in man. Let's wave our hands a bit, and make our statement with aggressive confidence. IDNNA has shown no activity in the human CNS at any level that has been evaluated. This sounds pretty good. Just don't go too far up there, and don't look too carefully. This is not as unscrupulous as it might sound since, in practical terms, the extremely high specific activities of the radioactive 122I that would be used, would dictate that only an extremely small amount of the drug would be required. One would be dealing, not with milligram quantities, but with microgram quantities, or less.
Some fifteen close analogues of IDNNA were prepared, to see if any had a better balance of biological properties. A valuable intermediate was an iodinated ketone that could be used either to synthesize IDNNA itself or, if it were to be made radio-labelled, it would allow the preparation of any desired radioactive analogue in a single synthetic step. The iodination of p-dimethoxybenzene with iodine monochloride in acetic acid gave 2,5-diiodo-1,4-dimethoxybenzene as white crystals from acetonitrile, with a mp of 167-168 °C. Anal. (C8H8I2O2) C,H. Treatment of this with an equivalent of butyllithium in ether, followed with N-methyl formanilide, gave 2,5-dimethoxy-4-iodobenzaldehyde as pale yellow crystals from ethanol, with a mp of 136-137 °C. Anal. (C9H9IO3) C,H. This, in solution in nitroethane with a small amount of anhydrous ammonium acetate, gave the nitrostyrene 1-(2,5-dimethoxy-4-iodophenyl)-2-nitropropene as gold-colored crystals from methanol, mp 119-120 °C. Anal. (C11H12INO4) C,H. This was smoothly reduced with ele-mental iron in acetic acid to give 2,5-dimethoxy-4-iodophenylacetone as white crystals from methylcyclopentane. These melted at 62-63 °C and were both spec-troscopically and analytically correct. Anal. (C11H13IO3) C,H.
This intermediate, when reductively aminated with dimethylamine, gives IDNNA identical in all respects to the product from the dimethylation of DOI above. But it has also been reacted with 131I NaI in acetic acid at 140 °C for 10 min, giving the radioactive compound by exchange, and this was reductively aminated with over a dozen amines to give radioactive products for animal assay. There was produced in this way, 2,5-dimethoxy-4-iodo-N-alkyl-amphetamine where the alkyl group was methyl, isopropyl, cyclopropylmethyl, hexyl, dodecyl, benzyl, cyanomethyl, and 3-(dimethylaminopropyl). Several dialkyl homologue were made, with the alkyl groups being dimethyl (IDNNA itself), diethyl, isopropyl-methyl, and benzyl-methyl. These specific homologues and analogues are tallied in the index, but a number of other things, such as hydrazine or hydroxylamine derivatives, were either too impure or made in amounts too small to be valid, and they are ignored.
The diethyl compound without the iodine is 2,5-dimethoxy-N,N-diethylamphetamine, which was prepared by the reductive alkylation of DMA with acetaldehyde and sodium cyanoborohydride. This product, DEDMA, was a clear white oil, bp 82-92 °C at 0.15 mm/Hg which did not form a crystalline hydrochloride. An interesting measure of just how different these N,N-dialkylated homologues can be from the psychedelic primary amines, pharmacologically, can be seen in the published report that the beta-hydroxy derivative of DEDMA is an antitussive, with a potency the same as codeine.
None of these many iodinated IDNNA analogues showed themselves to be superior to IDNNA itself, in the rat model, and none of them have been tasted for their psychedelic potential in man.
#91 IM; ISOMESCALINE; 2,3,4-TRIMETHOXYPHENETHYLAMINE
SYNTHESIS: A solution of 8.0 g 2,3,4-trimethoxybenzaldehyde in 125 mL nitromethane containing 1.4 g anhydrous ammonium acetate was held at reflux for 1.5 h. The conversion of the aldehyde to the nitrostyrene was optimum at this time, with a minimum development of a slow-moving spot as seen by thin layer chromatography on silica gel plates using CHCl3 as a developing solvent; the Rf of the aldehyde was 0.31 and the Rf of the nitrostyrene was 0.61. The excess nitromethane was removed under vacuum, and the residue was dissolved in 20 mL hot MeOH. On cooling, the yellow crystals that formed were removed by filtration, washed with cold MeOH and air dried yielding 4.7 g yellow crystals of 2,3,4-trimethoxy-'-nitrostyrene, with a mp of 73-74 °C. From the mother liquors, a second crop of 1.2 g was obtained.
A solution of 4.0 g LAH in 80 mL THF under He was cooled to 0 °C and vigorously stirred. There was added, dropwise, 2.7 mL of 100% H2SO4, followed by a solution of 4.7 g 2,3,4-trimethoxy-'-nitrostyrene in 40 mL anhydrous THF. The mixture was stirred at 0 °C for 1 h, at room temperature for 1 h, and then brought briefly to a reflux on the steam bath. After cooling again, the excess hydride was destroyed with 4.7 mL H2O in THF, followed by the addition of 18.8 mL 15% NaOH which was sufficient to convert the solids to a white and granular form. These were removed by filtration, the filter cake washed with THF, the mother liquor and filtrates combined, and the solvent removed under vacuum. The residue was added to dilute H2SO4, and washed with 2x75 mL CH2Cl2. The aqueous phase was made basic with 25% NaOH, and extracted with 2x50 mL CH2Cl2. The solvent was removed from these pooled extracts and the amber-colored residue distilled at 95-100 °C at 0.3 mm/Hg to provide 2.8 g of 2,3,4-trimethoxyphenethylamine as a white oil. This was dissolved in 20 mL IPA, neutralized with about 1 mL concentrated HCl, and diluted with 60 mL anhydrous Et2O. After filtering, Et2O-washing, and air drying, there was obtained 3.2 g of 2,3,4-trimethoxyphenethylamine hydrochloride (IM) as a white crystalline product.
DOSAGE: greater than 400 mg.
DURATION: unknown.
QUALITATIVE COMMENTS: (with 300 mg) No effects whatsoever.
(with 400 mg) Maybe a slight tingle at the hour-and-a-half point. Maybe not. Certainly nothing an hour later. Put this down as being without action.
EXTENSIONS AND COMMENTARY: Some fifty years ago this material was given the name "reciprocal mescaline" in that it was believed to exacerbate the clinical symptoms in schizophrenic patients. In the original report, one finds: RThus we have discovered an extremely remarkable dependency of the intoxicating action upon the position of the three methoxy groups. Mescaline, the 3,4,5-trimethoxy-'-phenethylamine, produces in the normal subject a much stronger over-all intoxication than in the schizophrenic patient, whereas 2,3,4-trimethoxy-'-phenethylamine has quite the opposite effect. It has little action in healthy individuals, being almost without intoxicating properties, but it is very potent in the schizophrenic. The metabolic conversion products of the "reciprocal" mescaline will be further studied as soon as the study of the metabolism of the proper mescaline is complete.
This is a pretty rich offering, and one that the present medical community has no qualms about discarding. At the bookkeeping level, the promised further studies have never appeared, so all may be forgotten as far as potential new discoveries might be concerned.
One recent related study has been reported, tying together isomescaline and schizophrenia. Through the use of radioactive labelling, the extent of demethylation (the metabolic removal of the methyl groups from the methoxyls) was determined in both schizophrenic patients and normal subjects. When there was a loading of the person with methionine (an amino acid that is the principal source of the body's methyl groups), the schizophrenics appeared to show a lesser amount of demethylation.
But might either of these two observations lead to a diagnostic test for schizophrenia? At the present time, the conventional thinking is that this probably cannot be. The illness has such social and genetic contributions, that no simple measure of a response to an almost-psychedelic, or minor shift of some urinary metabolite pattern could possibly be believed. No independent confirmation of these properties has been reported. But maybe these findings are valid. A major problem in following these leads does not involve any complex research protocols. What must be addressed are the present regulatory restrictions and the Federal law structure. And these are formidable obstacles.
#92 IP; ISOPROSCALINE; 3,5-DIMETHOXY-4-(i)-PROPOXYPHENETHYLAMINE
SYNTHESIS: A solution of 5.8 g of homosyringonitrile (see under ESCALINE for its preparation) and 13.6 g isopropyl iodide in 50 mL dry acetone was treated with 6.9 g finely powdered anhydrous K2CO3 and held at reflux on the steam bath. After 6 h another 5 mL of isopropyl iodide was added, and refluxing continued for an additional 12 h. The mixture was filtered and the solids washed with acetone. The mother liquor and washes were stripped of solvent under vacuum, The residue was taken up in dilute HCl, and extracted with 3x100 mL CH2Cl2. The pooled extracts (they were quite deeply yellow colored) were washed with 2x75 mL 5% NaOH, and finally once with dilute HCl. Removal of the solvent under vacuum yielded 9.8 g of an amber oil, which on distillation at 125-135 °C at 0.3 mm/Hg provided 6.0 g of 3,5-dimethoxy-4-(i)-propoxyphenylacetonitrile as a pale yellow oil. A pure reference sample is a white solid with a mp of 33-34 °C. Anal. (C13H17NO3) C,H,N.
A solution of AH was prepared by the cautious addition of 0.84 mL of 100% H2SO4 to 32 mL of 1.0 M LAH in THF, which was being vigorously stirred under He at ice-bath temperature. A solution of 5.93 g of 3,5-dimethoxy-4-(i)-propoxyphenylacetonitrile in 10 mL anhydrous THF was added dropwise. Stirring was continued for 30 min, then the reaction mixture was brought up to reflux on the steam bath for another 30 min. After cooling again to room temperature, 5 mL IPA was added to destroy the excess hydride, followed by about 10 mL of 15% NaOH, sufficient to make the aluminum salts loose, white, and filterable. The reaction mixture was filtered, the filter cake washed with IPA, the mother liquor and washes combined, and the solvent removed under vacuum. The residue (7.0 g of an amber oil) was dissolved in dilute H2SO4 and washed with 3x75 mL CH2Cl2. The aqueous phase was made basic with aqueous NaOH, and the product extracted with 3x75 mL CH2Cl2. The extracts were evaporated to a residue under vacuum, and this was distilled at 125-140 °C at 0.3 mm/Hg yielding 3.7 g of a colorless oil. This was dissolved in 15 mL IPA, neutralized with 50 drops of concentrated HCl which allowed the deposition of a white crystalline product. Dilution with anhydrous Et2O and filtration gave 3.7 g. of 3,5-dimethoxy-4-(i)-propoxyphenethylamine hydrochloride (IP) with a mp of 163-164 °C. Anal. (C13H22ClNO3) C,H,N. The catalytic hydrogenation process for reducing the nitrile that gives rise to escaline, also works with this material.
DOSAGE: 40 - 80 mg.
DURATION: 10 - 16 h.
QUALITATIVE COMMENTS: (with 75 mg) Starts slowly. I develop some queasiness, turning into nausea. Feels good to lie down and let go, but the uneasiness remains. Just beginning to break through in 2 hours. But the occasional sense of relief, the breaking into the open, were transient as new sources of discomfort were always being dredged up. Then for some reason I chose to dance. Letting go to dancing, a marvelous ecstatic experience, flowing with and being the energy, body feeling completely free. Noticing how this letting go got one completely out of the feeling of unease, as though attention simply needs to be put elsewhere. Comedown was very slow, gentle, euphoric; a very signicant experience. Sleep that night was impossible, but felt good to simply release to the feelings. Keeping mind still, no thinking, just allowing feelings to go where they wished, became more and more ecstatic. Tremendous feeling of confidence in life and the life process. Complete sense of resolution.
(with 80 mg) It took about two hours for the body to settle down. Emotions were true and well felt, a fact that is an all-important thing to me as it probably is to everyone else I know in this kind of exploration. Any sense that there is a dulling of the feeling and emotional area of the self is a negative, to be watched and noted as are other things such as disturbed sleep, unpleasant dreams, or irritability or depression the next day. I was interacting with others with a great deal of intensity. People found themselves wandering inside and out, listening to music, stirring soup, eating a bit and enjoying eating, talking, laughing a great deal, and being silent in great contentment. It's not a very silent material, though. Talking is too enjoyable. There was a slight descent noted at 6-7 hours, but very gentle and smooth. Slow and pleasant descent until about 12th hour, when sleep was attempted. Next day, everyone slightly irritable but good mood anyway. The next night I slept deeply and well, and awoke whole and in excellent mood.
EXTENSIONS AND COMMENTARY: These two excerpts give the color and complexity of IP. It has proven to be a completely fascinating phenethylamine. And, as with all the phenethylamines, there is an amphetamine that corresponds to it. This would be 3,5-dimethoxy-4-isopropoxyamphetamine, or 3C-IP. The prepa-ration of it would require access through the O-isopropoxylation product with syringaldehyde, followed by nitrostyrene formation with nitroethane, followed by reduction probably with lithium aluminum hydride. It has not been synthesized, as far as I know, and so it has probably not been evaluated in man. What would be the active level? It would probably be more potent than IP, but I would guess not by much. Maybe in the 30 milligram area.
A moment's aside for a couple of the words that are so much a part of the chemist's jargon. Room temperature, as used above, means the natural temperature that something comes to if it is put on the table and is neither heated nor cooled. The phrase, I discovered during my year at Gif, is completely un-understandable in French. A room has no temperature. Only things in rooms have temperatures. Their expression is more exact. The object achieves, in the French terminology, a temperature normale d'interieur, or about 15 to 16 °C. But in common laboratory parlance it has become the temperature d'ambiance.
And one finds the prefix "iso" used everywhere. Considerable care should be taken in the two different uses of the prefix "iso" in the nomenclature with the mescaline analogues. In general, the term "iso" means the other one of two possibilities. If you are allowed to paint a house only with green paint or red paint, and green is the color you actually use, then red could be called iso-green. With isoproscaline (here) there is a rearranging of the propyl group on the 4-oxygen of mescaline. It has been replaced with its branched analogue, the other of two possibilities, the isopropyl group. Everything is still with the 3,4,5-orientation on the benzene ring. However, with IM (isomescaline) there is a rearrangement of substitution pattern on the benzene ring, with the repositioning of the trimethoxyl substitution pattern from the 3,4,5- arrangement to the 2,3,4- arrangement. It has been the side-chain that has taken the other of two possible positions. The term "iso" must always be interpreted in precise context.
#93 IRIS; 5-ETHOXY-2-METHOXY-4-METHYLAMPHETAMINE
SYNTHESIS: To a solution of 9.5 g flaked KOH (10% excess) in 500 mL 95% EtOH there was added 20.4 g 4-methoxy-2-methylphenol (see under 2C-D for its preparation). This was followed with 23.5 g ethyl iodide, and the mixture was held at reflux overnight. The solvent was removed under vacuum and the residue suspended in 250 mL H2O. This was made strongly basic with NaOH and extracted with 3x50 mL CH2Cl2. Removal of the solvent gave 15.75 g of 2-ethoxy-5-methoxytoluene as an amber oil, which was used in the following step without further purification. Acidification of the aqueous phase followed by CH2Cl2 extraction gave, after removal of the solvent, crude recovered starting phenol as a dark brown crystalline solid. The reasonably pure phenol was best isolated by sequential extractions with portions of 80 °C H2O which, on cooling, deposited the phenol as white crystals.
A mixture of 38 mL POCl3 and 43 mL N-methylformanilide was allowed to incubate for 1 h and then there was added to it 15.7 g 2-ethoxy-5-methoxytoluene. This was heated in the steam bath for 2 h, then poured into 1 L H2O and allowed to stir overnight. The solids that formed were removed by filtration and H2O washed, giving 20.7 g of a crude, amber product. This was extracted with 2x150 mL boiling hexane which gave crystals on cooling. These were filtered and hexane washed, giving 12.85 g of 5-ethoxy-2-methoxy-4-methylbenzaldehyde as pale cream-colored solids with a mp of 75-76 °C. Recrystallization of an analytical sample from EtOH two times gave a product with a white color, and a mp of 81-82 °C.
To a solution of 11.35 g 5-ethoxy-2-methoxy-4-methylbenzaldehyde in 48 mL glacial acetic acid containing 4 g anhydrous ammonium acetate there was added 10 mL nitroethane, and the mixture heated on the steam bath for 2 h. Standing at room temperature overnight allowed a heavy crop of brilliant crystals to deposit. These were removed by filtration, washed cautiously with acetic acid, and air dried to give 8.6 g 1-(5-ethoxy-2-methoxy-4-methylphenyl)-2-nitropropene with a mp of 118-120 °C. Recrystallization of all from 200 mL boiling MeOH gave 8.3 g of lustrous crystals with a mp of 121-122 °C.
To a gently refluxing suspension of 6.4 g LAH in 500 mL anhydrous Et2O under a He atmosphere, there was added 8.1 g 1-(5-ethoxy-2-methoxy-4-methylphenyl)-2-nitropropene by allowing the condensing ether to drip into a shunted Soxhlet thimble containing the nitrostyrene. This effectively added a warm saturated solution of the nitrostyrene dropwise. Refluxing was maintained overnight, and the cooled reaction flask stirred for several additional days. The excess hydride was destroyed by the cautious addition of 400 mL H2O containing 40 g H2SO4. When the aqueous and Et2O layers were finally clear, they were separated, and 160 g of potassium sodium tartrate was dissolved in the aqueous fraction. Aqueous NaOH was then added until the pH was >9, and this was then extracted with 3x50 mL CH2Cl2. Evaporation of the solvent under vacuum produced an oil that was dissolved in anhydrous Et2O and saturated with anhydrous HCl gas. There appeared 5-ethoxy-2-methoxy-4-methylamphetamine hydrochloride (IRIS) as fine white crystals. These weighed, after filtration, Et2O washing, and air drying to constant weight, 5.3 g and had a mp of 192-193 °C. Recrystallization of an analytical sample from boiling CH3CN gave lustrous crystals with a mp of 196-197 °C with decomposition.
DOSAGE: greater than 9 mg.
DURATION: unknown.
QUALITATIVE COMMENTS: (with 7.5 mg) At about three hours I felt that I was at threshold, but an hour later there was nothing.
(with 9 mg) Maybe a little light headed? Maybe not. Little effect if any.
EXTENSIONS AND COMMENTARY: This is one of the ten Classic Ladies, the ten possible homologues of DOM, which I had discussed under ARIADNE (the first of the Ladies). The active level is unknown, but it is higher than 9 milligrams (the highest dose tried) and since DOM itself would have been smashingly active at this level, it is obvious that IRIS is a homologue with decreased potency.
This lack of activity brings up a fascinating point. I have referred to a drug's action on the mind, quite frequently in these notes, with the phrase "reasonably complex." By that, I do not mean that a drug's action simply shows many facets, and if these were to be tallied, the drug-mind interaction would become clear. There is quite a bit of importance intrinsically implied by the term, complex. Simple things, as we have come to appreciate and depend upon them in our day-to-day living, can have simple explanations. By this, I mean explanations that are both completely satisfactory and satisfactorily complete. Answers that have all the earmarks of being correct. What is the sum of two plus three, you ask? Let's try five. And for most of our needs, five is both factual and complete.
But some years ago, a mathematician named Gdel devised a proof for a theorem that anything that is reasonably complex cannot enjoy this luxury (I believe he used the word "interesting" rather than reasonably complex). If your collection of information is factual, it cannot be entirely complete. And if it is complete, it cannot be entirely factual. In short, we will never know, we cannot ever know, every fact that constitutes an explanation of something. A complete book of knowledge must contain errors, and an error-free book of knowledge must be incomplete.
There is a small warning light deep inside me that starts flashing any time I hear someone begin to advance an explanation of some reasonably complex phenomenon with an air of confidence that implies, "Here is how it works." What the speaker usually has is an intense familiarity with one particular discipline or specialty and the phenomenon is viewed through those eyes, often with the assurance that looking at it that way, intently enough and long enough, will reveal the complete explanation. And be attentive to the phrase, "We are not yet completely sure of exactly how it works." What is really meant is, RWe haven't the slightest idea of how it really works.
I must admit to some guilt in this matter, certainly as much as the next person. I am a chemist and I suspect that the way that the psychedelic drugs do their thing can eventually be understood through a comparison of the structures of the molecules that are active and those that are inactive. I put those that have methoxyl groups in pigeon hole #1, and those that are bicyclic into pigeon hole #2. And then, if pigeon hole #2 becomes more and more cluttered, I will subdivide the contents into pigeon hole #2A for bicyclics with heteroatoms and pigeon hole #2B for bicyclics without heteroatoms. The more information I can accumulate, the more pigeon holes I need.
But in the adjoining lab, there is a molecular biologist who feels that the eventual explanation for the action of the psychedelic drug will come from the analysis and understanding of the intimate geometry of the places in the brain where they act. These classification pigeon holes are called receptor sites. But they, too, can become more and more subdivided as they become cluttered. One reads of a new sub-sub type quite regularly in the literature. The favorite neurotransmitter of the moment, as far as the current thinking of how these marvelous drugs work, is serotonin, or 5-HT (for 5-hydroxytryptamine). There are 5-HT1 and 5-HT2A and 5-HT2B and (for all I know right now) 5-HT2C and 5-HT2D receptors, and I don't really think that either he or I have come much closer to understanding the mechanism of action.
And, since the mind is a reasonably complex system, Gdel has already informed us both that neither of us will be completely successful. Sometimes I feel that the pigeon hole approach to the classification of knowledge might actually limit our views of the problem. A Harvard Professor of Medicine recently noted: RWe must recognize for what it is, man's predilection for dividing things into tidy categories, irrespective of whether clarity is gained or lost thereby.
No. No one will ever have it all together. It is like sitting down in front of a jigsaw with a zillion zillion pieces spread all over the kitchen table. With diligent searching you will occasionally find a piece that matches another, but it rarely provides any insight into the final picture. That will remain a mystery, unless you had the chance to see the cover of the box in some other incarnation. But Oh my, what fun it is, whenever you do happen to find a new piece that fits°
This harangue is really a lengthy prelude to the story of putting an ethoxy group in place of a methoxy on the 2,5-dimethoxy skeleton of these psychedelic families. The making of IRIS was the first move in this direction, done back in 1976. One can have a pigeon hole that is named "Ethoxy In Place of Methoxy" and toss in there the names of perhaps twenty pairs of compounds, which differ from one another by just this feature. Yet when they are looked at from the potency point of view, there are some which show a decrease in potency (which is the case with IRIS and most of the Tweetios) and there are some which seem to maintain their potency (such as the TMA-2/MEM pair) and there are some where there is a distinct potency increase (the mescaline/escaline pair, for example).
What does one do to clarify the contents of this particular pigeon hole? The current fad would be to subdivide it into three subdivisions, maybe something like "Ethoxy in Place of Methoxy if 2- or 5-located" and REthoxy in Place of Methoxy if 4-located and other things 2,5S and "Ethoxy in Place of Methoxy if 4-located, and other things 3,5." The end point that soon becomes apparent, down the line, will be to have as many pigeon holes as compounds° And at the moment, this particular piece of the jigsaw puzzle doesn't seem to fit anywhere at all.
Perhaps both my neighboring molecular biologist and I are asking the wrong questions. I am looking at the molecules and asking, "What are they?" And he is following them and asking, "Where do they go?" And neither of us is fully attentive to the question, "What do they do?" It is so easy to replace the word "mind," in our inquiries, with the word "brain."
Yup. The operation of the mind can certainly be classified as a "reasonably complex" phenomenon. I prefer Gdel's term. The mind is without question an "interesting" phenomenon.
#94 J; BDB; 2-AMINO-1-(3,4-METHYLENEDIOXYPHENYL)BUTANE; 1-(1,3-BENZODIOXOL-5-YL)-2-BUTANAMINE
SYNTHESIS: The Grignard reagent of propyl bromide was made by the dropwise addition of 52 g 1-bromopropane to a stirred suspension of 14 g magnesium turnings in 50 mL anhydrous Et2O. After the addition, stirring was continued for 10 min, and then a solution of 50 g piperonal in 200 mL anhydrous Et2O was added over the course of 30 min. The reaction mixture was heated at reflux for 8 h, then cooled with an external ice bath. It was quenched with the addition of a solution of 75 mL cold, saturated aqueous ammonium chloride. The formed solids were removed by filtration, and the two-phase filtrate separated. The organic phase was washed with 3x200 mL dilute HCl, dried over anhydrous MgSO4, and the solvent removed under vacuum. The crude 62.2 g of 1-(3,4-methylenedioxyphenyl)-2-butanol, which contained a small amount of the olefin that formed by dehydration, was distilled at 98 °C at 0.07 mm/Hg to give an analytical sample, but the crude isolate served well in the next reaction. Anal. (C11H14O3) C,H.
A mixture of 65 g crude 1-(3,4-methylenedioxyphenyl)-2-butanol and 1 g finely powdered potassium bisulfate was heated with a soft flame until the internal temperature reached 170 °C and H2O was no longer evolved. The entire reaction mixture was then distilled at 100-110 °C at 0.8 mm/Hg to give 55 g of 1-(3,4-methylenedioxyphenyl)-1-butene as a colorless oil. Anal. (C11H12O2) C,H.
To 240 mL of stirred and cooled formic acid there was added 30 mL H2O followed, slowly, by 45 mL of 35% hydrogen peroxide. There was then added a solution of 48 g 1-(3,4-methylenedioxyphenyl)-1-butene in 240 mL acetone at a rate that maintained the internal temperature at less than 40 °C. After the addition, the reaction mixture was allowed to stand and stir for several additional days. The excess volatiles were removed under vacuum with the temperature never allowed to exceed 40 °C. The residue was dissolved in 90 mL MeOH and diluted with 450 mL 15% H2SO4. This mixture was heated on the steam bath for 2.5 h, cooled, and then extracted with 3x100 mL Et2O. The extracts were pooled, washed with 2x200 mL H2O, 2x200 mL 5% NaOH, 2x200 mL brine, and then dried over anhydrous MgSO4. After removal of the solvent under vacuum, the residue was distilled at 105-135 °C at 0.3 mm/Hg to give 28.2 g 1-(3,4-methylenedioxyphenyl)-2-butanone as an amber oil. Redistillation gave a colorless oil, with a bp of 98 °C at 0.11 mm/Hg. Anal. (C11H12O3) C,H. This intermediate ketone could be prepared by the Wittig reaction between piperonal and the derivative of triphenylphosphonium propyl bromide and dibutyldisulfide, followed by hydrolysis in a HCl/acetic acid mixture, but the yields were no better, Efforts to prepare this ketone by the iron and acid reduction of the appropriate nitrostyrene (1-(3,4-methylenedioxyphenyl)-2-nitro-1-butene, mp 64-65 °C) were thwarted by the consistently unsatisfactory yield of the precursor from the reaction between piperonal and 1-nitropropane.
A stirred solution of 20 g anhydrous ammonium acetate and 4.6 g 1-(3,4-methylenedioxyphenyl)-2-butanone in 50 mL MeOH was treated with 1.57 g sodium cyanoborohydride. Droplets of HCl were added as needed to maintain the pH at approximately 6. The reaction mixture was made basic with the addition of 250 mL dilute NaOH and extracted with 3x100 mL CH2Cl2. The pooled organic extracts were extracted with 2x100 mL dilute H2SO4, the pooled aqueous extracts made basic again, and extracted again with 2x100 mL CH2Cl2. Removal of the solvent gave a residue which was distilled to give 2.6 g of a colorless oil which was dissolved in 15 mL IPA, neutralized with concentrated HCl, and diluted with an equal volume of anhydrous Et2O. Crystals of 2-amino-1-(3,4-methylenedioxyphenyl)butane hydrochloride (J) separated slowly. After filtering, Et2O washing, and air drying there was obtained 2.8 g of white crystals that melted at 159-161 °C. Anal. (C11H16ClNO2) C,H,N.
DOSAGE: 150 - 230 mg.
DURATION: 4 - 8 h.
QUALITATIVE COMMENTS: (with 175 mg) The first stirrings were evident in a half hour, pleasant feelings, and without any untoward body effects. Within another half hour I was at a plus 2 and there it leveled off. I would be reluctant to drive a car, but I could were it necessary. There were no visual distortions, no giddiness, no introspective urges, and no rise to a psychedelic intoxication of any significance. After about an hour and a half at this level, I gradually dropped back over another two hours. Afterwards I was quite fatigued and languorous.
(with 200 mg and a 75 mg supplement) RA very strong climb, and a very good, interior feeling. It has some of the MDMA properties, but it is difficult to concentrate on any one point. There is a tendency to slide off. Excellent emotional affect; music is fine but not gripping. Someone had used the phrase, mental nystagmus, and there is something valid there. The supplement was taken at the 2 hour point when I was already aware of some dropping, and its action was noticed in about a half hour.
(with 230 mg) Physically, there was a bit of dry mouth but no teeth clenching, some nystagmus, maybe the slightest bit of dizziness, very anorexic, and it is not a decongestant. Mentally, it is extremely benign and pleasant, funny and good-humored. No visuals. Peaceful. Easy silences, easy talking. More stoning than MDMA.
EXTENSIONS AND COMMENTARY: In general, all subjects who have explored J have accepted it and commented favorably. Perhaps those who have used supplements (in an imitation of the common MDMA procedure) achieved an additional period of effect, but also tended to drop to baseline afterwards more rapidly. The physical side effects, such as teeth clench and nystagmus, were infrequent. The consensus is that J is a bit more "stoning" than MDMA, more like MDA, but with a chronology that is very much the same.
Two nomenclature problems have to be faced in the naming of these compounds. One deals with the Chemical Abstracts terminology as contrasted with the logical and intuitive terminology. The other invokes the concept of the Muni-Metro, delightfully simple, but neither Chemical Abstracts-approved nor intuitive in form. The first problem is addressed here; the second is discussed where it better belongs, under the N-methyl homologue of J (see under METHYL-J).
In short, the two-ring system of J, or of any of the MDA-MDMA family of drugs, can be named as one ring being attached to the other, or by a single term that encompasses both. The first procedure, an old friend with chemists and the one that had been used for years in the abstracting services, calls the combination methylenedioxybenzene and, as a prefix, it becomes methylenedioxyphenyl-something. The benzene or the phenyl-something is the foundation of the name, and there happens to be a methylenedioxy-ring attached to it. On this basis, this compound J should be named as if it had no methylenedioxy ring anywhere, and then simply attach the new ring as an afterthought. So, the one-ring parent of J is 1-phenyl-2-aminobutane, and J is 1-(3,4-methylenedioxyphenyl)-2-aminobutane (or, to be a purist, the amino should alphabetically come first, to give 2-amino-1-(3,4-methylene-dioxyphenyl)butane). The synthesis of the chemical intermediates given above uses this old-fashioned nomenclature.
But the name currently in vogue for this two-ring system is 1,3-benzodioxole. As a prefix it becomes 1,3-benzodioxol-5-yl-something, and so J would be called 1-(1,3-benzodioxol-5-yl)-2-aminobutane. This is the source of the code name BDB. And the N-methyl homologue, the alpha-ethyl analogue of MDMA, is named MBDB, or METHYL-J, and is with its own separate entry in this footnote.
There is a psychological nuance to this new nomenclature. The virtues and potential medical value of MDMA lie in its most remarkable property of facilitating communication and introspective states without an overlay of psychedelic action. This property has prompted the coining of a new pharmacological class name, Entactogen, which comes from the Greek roots for "touching within." But MDMA has been badly smeared in both the public and the scientific view, by its wide popular misuse, its precipitous placement into a Schedule I category of the Federal Drug Law, and a flood of negative neurotoxicological findings in animal studies. There are some properties of both this compound and its methyl-homologue that suggest this "entactogen" world, so why not avoid the RMDS prefix that, in many eyes, is pejorative? Stick with the totally obscure chemical names, and call them BDB and MBDB. Or, even more simply, J and METHYL-J.
#95 LOPHOPHINE; 3-METHOXY-4,5-METHYLENEDIOXYPHENETHYLAMINE
SYNTHESIS: A solution of 50 g myristicinaldehyde (3-methoxy-4,5-methylenedioxybenzaldehyde, see under MMDA for its preparation) in 200 mL acetic acid was treated with 33 mL nitromethane and 17.4 g anhydrous ammonium acetate and held on the steam bath for 5 h. The reaction mixture was diluted with a little H2O and cooled in an external ice-acetone bath. A heavy crop of yellow crystals formed, which were removed by filtration, washed with cold acetic acid, and dried to constant weight. There was thus obtained 19.3 g 3-methoxy-4,5-methylenedioxy-'-nitrostyrene with a mp of 210-212 °C. The mother liquors were diluted with H2O, and extracted with 3x100 mL CH2Cl2. The pooled extracts were washed with 5% NaOH, and the solvent removed under vacuum yielding 34 g of a dark residue that was largely unreacted aldehyde. This residue was reprocessed in acetic acid with nitromethane and ammonium acetate, as described above, and provided an additional 8.1 g of the nitrostyrene with the same mp.
A suspension of 25 g LAH in 1.5 L anhydrous Et2O in an inert atmosphere was stirred magnetically, and brought up to a gentle reflux. Through a Soxhlet condenser modified to allow Et2O to return continuously to the reaction mixture, there was added 27.0 g of 3-methoxy-4,5-methylenedioxy-'-nitrostyrene. The addition require many h, and when it was completed, the reaction was held at reflux for an additional 9 days. After cooling the reaction mixture in an external ice bath, the excess hydride was destroyed by the cautious addition of dilute H2SO4. The final amount used was 1800 mL H2O containing 133 g H2SO4. The phases were separated, and the aqueous phase was washed with 2x100 mL Et2O. To it was then added 625 g potassium sodium tartrate, and sufficient base to bring the pH to >9. This was extracted with 3x250 mL CH2Cl2, and the pooled extracts stripped of solvent under vacuum. The residue was dissolved in anhydrous Et2O and saturated with anhydrous HCl gas, giving a heavy crystallization of salts. These were removed by filtration, Et2O washed, and air dried, to give 17.7 g 3-methoxy-4,5-methylenedioxyphenethylamine (LOPHOPHINE) as an off-white solid with a mp of 160-161 °C. This was dissolved in CH3CN containing 5% EtOH, decolorized with activated charcoal, filtered, and the removed charcoal washed with boiling CH3CN. Slow cooling of the solution provided 11.7 g of a white product which melted at 164-164.5 °C.
DOSAGE: greater than 200 mg.
DURATION: unknown.
QUALITATIVE COMMENTS: (with 150 mg) Between two and five hours, very peaceful and euphoric mood elevation, similar to mescaline, but without any visual distortion. Mild enhancement of color perception, possibly a function of mood elevation. There was no nausea, no eyes-closed vision. Slept easily that evening.
(with 250 mg) Possibly something of a threshold effect from 2:30 to 4:30 of the experiment. Intangible, and certainly there is nothing an hour later.
EXTENSIONS AND COMMENTARY: It looks as if this compound is not active. There is an excellent argument as to why it really should be, and the fact that it is not active is completely unexpected. Let me try to explain.
Quite simply, mescaline is a major component and a centrally active alkaloid of the Peyote plant. It is a phenethylamine, which can undergo a cyclization within the plant to produce a pile of derivatives (tetrahydroisoquinolines) such as anhalonine and O-methylanhalonidine that are marvelously complex alkaloids, all natural components of this magical cactus. But there is another pile of derivatives (tetrahydroisoquinolines) such as anhalonine, and lophophorine, and peyophorine which are the logical cyclization products of another phenethylamine which does not exist in the cactus. It should be there, but it is not. If it were there it would be the natural precursor to a host of bicyclic alkaloids, but it is absent. This is 3-methoxy-4,5-methylenedioxyphenethylamine. I feel that some day it will be discovered as a plant component, and when it is it can be given a name that reflects the generic binomial of the plant. And since the plant has been known as Lophophora williamsii, why not give a name to this compound (which should be in the plant), one derived from the Latin name, but one that has never before been used? What about LOPHOPHINE? And so, I have named it, but I have not found it, nor has anyone else. Yet.
It is inevitable that this simple and most appealing precursor will be found to be present in the cactus, at some future time when we will have tools of sufficient sensitivity to detect it. And certainly, it would be reasonable to expect it to be an active psychedelic, and to be as interesting in man as its close cousin, mescaline. But, at the present time, LOPHOPHINE is not known to be present in the plant, and it is not known to be active in man. I am confident that both statuses will change in the future.
#96 M; MESCALINE; 3,4,5-TRIMETHOXYPHENETHYLAMINE
SYNTHESIS: A solution of 20 g 3,4,5-trimethoxybenzaldehyde, 40 mL nitromethane, and 20 mL cyclohexylamine in 200 mL of acetic acid was heated on the steam bath for 1 h. The reaction mixture was then diluted slowly and with good stirring, with 400 mL H2O, which allowed the formation of a heavy yellow crystalline mass. This was removed by filtration, washed with H2O, and sucked as dry as possible. Recrystallization from boiling MeOH (15 mL/g) yielded, after filtration and air drying, '-nitro-3,4,5-trimethoxystyrene as bright yellow crystals weighing 18.5 g. An alternate synthesis was effective, using an excess of nitromethane as solvent as well as reagent, if the amount of ammonium acetate catalysis was kept small. A solution of 20 g 3,4,5-trimethoxybenzaldehyde in 40 mL nitromethane containing 1 g anhydrous ammonium acetate was heated on the steam bath for 4 h. The solvent was stripped under vacuum and the residual yellow oil was dissolved in two volumes of hot MeOH, decanted from some insolubles, and allowed to cool. The crystals formed are removed by filtration, washed with MeOH and air dried yielding 14.2 g. of bright yellow crystals of '-nitro-3,4,5-trimethoxystyrene. The use of these proportions but with 3.5 g ammonium acetate gave extensive side-reaction products even when worked up after only 1.5 h heating. The yield of nitrostyrene was, in this latter case, unsatisfactory.
To a gently refluxing suspension of 2 g LAH in 200 mL Et2O, there was added 2.4 g '-nitro-3,4,5-trimethoxystyrene as a saturated Et2O solution by use of a Soxhlet extraction condenser modified to allow the continuous return of condensed solvent through the thimble. After the addition was complete, the refluxing conditions were maintained for another 48 h. After cooling the reaction mixture, a total of 150 mL of 1.5 N H2SO4 was cautiously added, destroying the excess hydride and untimately providing two clear phases. These were separated, and the aqueous phase was washed once with 50 mL Et2O. There was then added 50 g potassium sodium tartrate, followed by sufficient NaOH to bring the pH >9. This was then extracted with 3x75 mL CH2Cl2, and the solvent from the pooled extracts was removed under vacuum. The residue was distilled at 120-130 °C at 0.3 mm/Hg giving a white oil that was dissolved in 10 mL IPA and neutralized with concentrated HCl. The white crystals that formed were diluted with 25 mL Et2O, removed by filtration, and air dried to provide 2.1 g 3,4,5-trimethoxyphenethylamine hydrochloride (M) as glistening white crystals. The sulfate salt formed spectacular crystals from water, but had a broad and uncharacteristic mp. An alternate synthesis can employ 3,4,5-trimethoxyphenylacetonitrile, as described under '-D.
DOSAGE: 200-400 mg (as the sulfate salt), 178-256 mg (as the hydrochloride salt).
DURATION: 10-12 h
QUALITATIVE COMMENTS: (with 300 mg) I would have liked to, and was expecting to, have an exciting visual day, but I seemed to be unable to escape self-analysis. At the peak of the experience I was quite intoxicated and hyper with energy, so that it was not hard to move around. I was quite restless. But I spent most of the day in considerable agony, attempting to break through without success. I learned a great deal about myself and my inner workings. Everything almost was, but in the final analysis, wasn't. I began to become aware of a point, a brilliant white light, that seemed to be where God was entering, and it was inconceivably wonderful to perceive it and to be close to it. One wished for it to approach with all one's heart. I could see that people would sit and meditate for hours on end just in the hope that this little bit of light would contact them. I begged for it to continue and come closer but it did not. It faded away not to return in that particular guise the rest of the day. Listening to Mozart's Requiem, there were magnificent heights of beauty and glory. The world was so far away from God, and nothing was more important than getting back in touch with Him. But I saw how we created the nuclear fiasco to threaten the existence of the planet, as if it would be only through the threat of complete annihilation that people might wake up and begin to become concerned about each other. And so also with the famines in Africa. Many similar scenes of joy and despair kept me in balance. I ended up the experience in a very peaceful space, feeling that though I had been through a lot, I had accomplished a great deal. I felt wonderful, free, and clear.
(with 350 mg) Once I got through the nausea stage, I ventured out-of-doors and I was aware of an intensification of color and a considerable change in the texture of the cloth of my skirt and in the concrete of the sidewalk, and in the flowers and leaves that were handed me by an observer. I experienced the desire to laugh hysterically at what I could only describe as the completely ridiculous state of the entire world. Although I was afraid of motion, I was persuaded to take a ride in a car. The driver turned on the radio and suddenly the music 'The March of the Siamese Children' from 'The King and I' became the most perfect background music for the parody of real life which was indeed the normal activity of Telegraph Avenue on any Saturday morning. The perfectly ordinary people on their perfectly ordinary errands were clearly the most cleverly contrived set of characters all performing all manners of eccentric activities for our particular hilarity and enjoyment. I felt that I was at the same time both observing and performing in an outrageous moving picture. I experienced one moment of transcendant happiness when, while passing Epworth Hall, I looked out of the window of the car and up at the building and I was suddenly in Italy looking up at a gay apartment building with its shutters flung open in sunshine, and with its window boxes with flowers. We stopped at a spot overlooking the bay, but I found the view uninteresting and the sun uncomfortable. I sat there on the seat of the car looking down at the ground, and the earth became a mosaic of beautiful stones which had been placed in an intricate design which soon all began to move in a serpentine manner. Then I became aware that I was looking at the skin of a beautiful snake Q all the ground around me was this same huge creature and we were all standing on the back of this gigantic and beautiful reptile. The experience was very pleasing and I felt no revulsion. Just then, another automobile stopped to look at the view and I experienced my first real feeling of persecution and I wanted very much to leave.
(with 400 mg) During the initial phase of the intoxication (between 2 and 3 hours) everything seemed to have a humorous interpretation. People's faces are in caricature, small cars seem to be chasing big cars, and all cars coming towards me seem to have faces. This one is a duchess moving in regal pomp, that one is a wizened old man running away from someone. A remarkable effect of this drug is the extreme empathy felt for all small things; a stone, a flower, an insect. I believe that it would be impossible to harm anything Q to commit an overt harmful or painful act on anyone or anything is beyond one's capabilities. One cannot pluck a flower Q and even to walk upon a gravel path requires one to pick his footing carefully, to avoid hurting or disturbing the stones. I found the color perception to be the most striking aspect of the experience. The slightest difference of shade could be amplified to extreme contrast. Many subtle hues became phosphorescent in intensity. Saturated colors were often unchanged, but they were surrounded by cascades of new colors tumbling over the edges.
(with 400 mg) It took a long time to come on and I was afraid that I had done it wrong but my concerns were soon ended. The world soon became transformed where objects glowed as if from an inner illumination and my body sprang to life. The sense of my body, being alive in my muscles and sinews, filled me with enormous joy. I watched Ermina fill to brimming with animal spirit, her features tranformed, her body cat-like in her graceful natural movement. I was stopped in my tracks. The world seemed to hold its breath as the cat changed again into the Goddess. As she shed her clothes, she shed her ego and when the dance began, Ermina was no more. There was only the dance without the slightest self-consconciousness. How can anything so beautiful be chained and changed by other's expectations? I became aware of myself in her and as we looked deeply into one another my boundaries disappeared and I became her looking at me.
EXTENSIONS AND COMMENTARY: Mescaline is one of the oldest psychedelics known to man. It is the major active component of the small dumpling cactus known as Peyote. It grows wild in the Southwestern United States and in Northern Mexico, and has been used as an intimate component of a number of religious traditions amongst the native Indians of these areas. The cactus has the botanical name of Lophophora williamsii or Anhalonium lewinii and is immediately recognizable by its small round shape and the appearance of tufts of soft fuzz in place of the more conventional spines. The dried plant material has been classically used with anywhere from a few to a couple of dozen of the hard tops, called buttons, being consumed in the course of a ceremony.
Throughout the more recently published record of clinical human studies with mescaline, it has been used in the form of the synthetic material, and has usually been administered as the sulfate salt. Although this form has a miserable melting point (it contains water of crystallization, and the exact melting point depends on the rate of heating of the sample) it nonetheless forms magnificent crystals from water. Long, glistening needles that are, in a sense, its signature and its mark of purity. The dosages associated with the above "qualitative comments" are given as if measured as the sulfate, although the actual form used was usually the hydrochloride salt. The conversion factor is given under "dosage" above.
Mescaline has always been the central standard against which all other compounds are viewed. Even the United States Chemical Warfare group, in their human studies of a number of substituted phenethylamines, used mescaline as the reference material for both quantitative and qualitative comparisons. The Edgewood Arsenal code number for it was EA-1306. All psychedelics are given properties that are something like "twice the potency of mescaline" or "twice as long-lived as mescaline." This simple drug is truly the central prototype against which everything else is measured. The earliest studies with the "psychotomimetic amphetamines" had quantitative psychological numbers attached that read as "mescaline units." Mescaline was cast in concrete as being active at the 3.75 mg/kg level. That means for a 80 kilogram person (a 170 pound person) a dose of 300 milligrams. If a new compound proved to be active at 30 milligrams, there was a M.U. level of 10 put into the published literature. The behavioral biologists were happy, because now they had numbers to represent psychological properties. But in truth, none of this represented the magic of this material, the nature of the experience itself. That is why, in this Book II, there is only one line given to "dosage," but a full page given to "qualitative comments."
Four simple N-modified mescaline analogues are of interest in that they are natural and have been explored in man.
The N-acetyl analogue has been found in the peyote plant, and it is also a major metabolite of mescaline in man. It is made by the gentle reaction of mescaline with acetic anhydride (a bit too much heat, and the product N-acetyl mescaline will cyclize to a dihydroisoquinoline, itself a fine white crystalline solid, mp 160-161 °C) and can be recrystallized from boiling toluene. A number of human trials with this amide at levels in the 300 to 750 milligrams range have shown it to be with very little activity. At the highest levels there have been suggestions of drowsiness. Certainly there were none of the classic mescaline psychedelic effects.
If free base mescaline is brought into reaction with ethyl formate (to produce the amide, N-formylmescaline) and subsequently reduced (with lithium aluminum hydride) it is converted to the N-methyl homologue. This base has also been found as a trace component in the Peyote cactus. And the effects of N-methylation of other psychedelic drugs have been commented upon elsewhere in these recipes, all with consistently negative results (with the noteworthy exception of the conversion of MDA to MDMA). Here, too, there is no obvious activity in man, although the levels assayed were only up to 25 milligrams.
N,N-Dimethylmescaline has been given the trivial name of Trichocerine as it has been found as a natural product in several cacti of the Trichocereus Genus but, interestingly, never in any Peyote variant. It also has proven inactive in man in dosages in excess of 500 milligrams, administered parenterally. This observation, the absence of activity of a simple tertiary amine, has been exploited in the development of several iodinated radiopharmaceuticals that are mentioned elsewhere in this book.
The fourth modification is the compound with the nitrogen atom oxidatively removed from the scene. This is the mescaline metabolite, 3,4,5-trimethoxyphenylacetic acid, or TMPEA. Human dosages up to 750 milligrams orally failed to produce either physiological or psychological changes.
One additional manipulation with some of these structures has been made and should be mentioned. These are the analogues with an oxygen atom inserted between the aromatic ring and the aliphatic chain. They are, in essence, aminoethyl phenyl ethers. The first is related to mescaline itself, 2-(3,4,5-trimethoxyphenoxy)ethylamine. Human trials were conducted over the dose range of 10 to 300 milligrams and there were no effects observed. The second is related to trichocerine, N,N-dimethyl-2-(3,4,5-trimethoxyphenoxy)ethylamine. It was inactive in man over the range of 10 to 400 milligrams. Mescaline, at a dose of 420 milligrams, served as the control in these studies.
#97 4-MA; PMA; 4-METHOXYAMPHETAMINE
SYNTHESIS: A solution of 27.2 g anisaldehyde and 18.0 g nitroethane in 300 mL benzene was treated with 2.0 mL cyclohexane and refluxed using a Dean Stark trap until H2O ceased to accumulate. A total of 3.8 mL was generated over about 5 days. After the removal of the solvent under vacuum, the viscous red oily residue was cooled and it spontaneously crystallized. This was ground under an equal volume of MeOH, producing lemon-yellow crystals of 1-(4-methoxyphenyl)-2-nitropropene. The final yield was 27.4 g of product with a mp of 45-46 °C. Recrystallization from 4 volumes MeOH did not improve the mp. An excellent alternate synthesis with a comparable yield involved letting a solution of equimolar amounts of the aldehyde and nitro-ethane and a tenth mole of n-amylamine stand in the dark at room temperature for a couple of weeks. The product spontaneously crystal-lized, and could be recrystallized from MeOH. The more conventional synthesis involving acetic acid as a solvent and ammonium acetate as a catalyst, produced a poor yield of the nitrostyrene and it was difficult to separate from the white diacetate of the starting anisaldehyde, mp 59-60 °C.
A suspension of 32 g LAH in 1 L anhydrous Et2O was well stirred and 32.6 g 1-(4-methoxyphenyl)-2-nitropropene in Et2O was added at a rate that maintained a reflux. After the addition was complete, reflux was continued for 48 h. The reaction mixture was cooled, and the excess hydride was destroyed by the cautious addition of dilute H2SO4. The Et2O was separated, and extracted with additional aqueous H2SO4. A solution of 700 g potassium sodium tartrate in 600 mL H2O was added, and the pH brought to >9 with 25% NaOH. This aqueous phase was extracted with 3x200 mL CH2Cl2 which provided, after removal of the solvent, 32.5 g of a clear amber oil. This was dissolved in 100 mL IPA, neutralized with concentrated HCl, and then diluted with 300 mL anhydrous Et2O. There was obtained white crystals of 4-methoxyamphetamine hydrochloride (4-MA) that weighed, after filtering, Et2O washing and air drying, 22.2 g and had a mp of 208-209 °C. The amphetamine metabolite, 4-hydroxyamphetamine hydrochloride (4-HA), was prepared by heating 5.0 g 4-MA in 20 mL concentrated HCl at 15 lbs/in. After recrystal-lization from aqueous EtOH, the product weighed 3.8 g and had a mp of 171-172 °C.
DOSAGE: 50 - 80 mg.
DURATION: short.
QUALITATIVE COMMENTS: (with 60 mg) At just over an hour, there was a sudden blood pressure rise, with the systolic going up 55 mm. This was maintained for another hour. I found the effects reminiscent of DET, distinct after-images, and some parasthesia. I was without any residue by early evening (after 5 hours).
(with 70 mg) It hit quite suddenly. I had a feeling of druggedness, almost an alcohol-like intoxication, and I never was really high in the psychedelic sense.
EXTENSIONS AND COMMENTARY: This is another of the essential amphetamines, because of the appearance of the 4-methoxy group in two most important essential oils. These are the allylbenzene (estragole or esdragol) and the propenyl isomer (anethole). Their natural sources have been discussed under TMA.
Two comments are warranted concerning 4-MA, one of scientific interest, and the other about a social tragedy.
A major metabolites of amphetamine is 4-hydroxyamphetamine, from oxidation at the 4-position. It has been long known that with chronic amphetamine usage there is the generation of tolerance, which encourages ever-increasing doses to be used. When the daily load gets up around one or two hundred milligrams, the subject can become quite psychotic. The question was asked: might the chronic amphetamine user be methylating his endogenously produced 4-hydroxyamphet-amine to produce 4-methoxyamphetamine (4-MA), and maybe this is the agent that promotes the psychosis? To address this question, several studies were done with normal subjects, about 20 years ago, to see if 4-MA might produce a psychotic state (it didn't at the highest levels tried, 75 milligrams) and to see if it was excreted to some extent unchanged in the urines of these normal subjects (it was seen even at the lowest dosage tried, 10 milligrams). It produced excitation and other central effects, it produced adrenergic pressor effects, and it consistently produced measur-able quantities of 4-MA in the urine, but it produced no amphetamine-like crazies. And since the administration of up to 600 milligrams of amphetamine produced no detectable 4-MA in the urine, this theory of psychotomimesis is not valid.
On the tragic side, a few years later, 4-MA became widely distributed in both the US (as the sulfate salt) and in Canada (as the hydrochloride), perhaps in-spired by some studies in rats that had reported that it was second only to LSD in potency as a hallucinogen. The several deaths that occurred probably followed overdose, and it was clear that 4-MA was involved as it had been isolated from both urine and tissue during post mortems. It had been sold under the names of Chicken Power and Chicken Yellow, and was promoted as being MDA. I could find no record of a typical street dosage, but comments collected in association with the deaths implied that the ingested quantites were in the hundreds of milligrams. Rrecently, the ethoxy homologue, 4-EA, appeared on the streets of Canada. The dosage, again, was not reported. It was promptly illegalized there.
The two positional analogues of 4-MA are known; vis., 2-MA and 3-MA. Their synthesis is straightforward, in imitation of that for 4-MA above. The meta-compound, 3-MA, has been metabolically explored in man, but no central effects were noted at a 50 milligram dose (2x25 milligrams, separated by three hours). There appears to be no report of any human trial of 2-MA. The N-methyl homologue of 2-MA is a commercial adrenergic bronchodilator called Methoxyphenamine, or Orthoxine. It has been used in the prevention of acute asthma attacks in doses of up to 200 milligrams, with only slight central stimulation. The N-methyl homologues of 3-MA and 4-MA are known, and the latter compound is the stuff of a separate entry in this book.
#98 MADAM-6; 2,N-DIMETHYL-4,5-METHYLENEDIOXYAMPHETAMINE
SYNTHESIS: A mixture of 102 g POCl3 and 115 g N-methylformanilide was allowed to stand for 0.5 h at room temperature during which time it turned a deep claret color. To this there was added 45 g 3,4-methylenedioxytoluene and the mixture was held on the steam bath for 3 h. It was then added to 3 L H2O. Stirring was continued until the oil which had separated had become quite firm. This was removed by filtration to give a greenish, somewhat gummy, crystalline solid, which was finely ground under 40 mL MeOH and again filtered giving, when air dried, 25 g of an almost white solid. Recrystallization of a small sample from methylcyclopentane gave ivory-colored glistening crystals of 2-methyl-4,5-methylenedioxybenzaldehyde with a mp of 88.5-89.5 °C. In the infra-red, the carbonyl was identical to that of the starting piperonal (1690 cm-1) but the fingerprint was different and unique, with bands at 868, 929, 1040 and 1052 cm-1.
A solution of 23 g 2-methyl-4,5-methylenedioxybenzaldehyde in 150 mL nitroethane was treated with 2.0 g anhydrous ammonium acetate and heated on the steam bath for 9 h. The excess solvent was removed under vacuum to give a dark yellow oil which was dissolved in 40 mL hot MeOH and allowed to crystallize. The solids were removed by filtration, washed modestly with MeOH and air dried, to give 21.2 g of 1-(2-methyl-4,5-methylenedioxyphenyl)-2-nitropropene as beautiful yellow crystals with a mp of 116-118 °C. Recrystallization of an analytical sample from MeOH gave lustrous bright yellow crystals with a mp of 120-121 °C. Anal. (C11H11NO4) C,H,N.
A suspension of 54 g electrolytic elemental iron in 240 g glacial acetic acid was warmed on the steam bath, with frequent stirring. When the reaction between them started, there was added, a portion at a time, a solution of 18.2 g 1-(2-methyl-4,5-methylenedioxyphenyl)-2-nitropropene in 125 mL warm acetic acid. The orange color of the nitrostyrene solution became quite reddish, white solids of iron acetate appeared, and a dark tomato-colored crust formed which was continuously broken back into the reaction mixture. Heating was continued for 1.5 h, and then all was poured into 2 L H2O. All the insolubles were removed by filtration, and these were washed well with CH2Cl2. The filtrate and washes were combined, the phases separated, and the aqueous phase extracted with 2x100 mL additional CH2Cl2. The combined organics were washed with 5% NaOH, and the solvent removed under vacuum. The residue weighed 15.9 g, and was distilled at 90-110 °C at 0.4 mm/Hg to give 13.9 g of 2-methyl-4,5-methylenedioxyphenylacetone that spontaneously crystallized. A small sample from methylcyclopentane had a mp of 52-53 °C, another from hexane a mp of 53-54 °C, and another from MeOH a mp of 54-55 °C. Anal. (C11H12O3) H; C calcd, 68.73; found 67.87, 67.84.
To a stirred solution of 30 g methylamine hydrochloride in 200 mL warm MeOH there was added 13.5 g 2-methyl-4,5-methylenedioxyphenylacetone followed, after returning to room temperature, by 7 g sodium cyanoborohydride. There was added HCl as needed to maintain the pH at approximately orange on external damp universal pH paper. After a few days, the reaction ceased generating base, and all was poured into 2 L dilute H2SO4 (caution, HCN evolved). This was washed with 3x75 mL CH2Cl2, made basic with 25% NaOH, and the resulting mixture extracted with 3x100 CH2Cl2. The pooled extracts were stripped of solvent under vacuum and the residue, 15 g of a pale amber oil, was distilled at 95-110 °C at 0.4 mm/Hg. There was obtained 12.3 g of a white oil that was dissolved in 60 mL IPA, neutralized with approximately 5.5 mL concentrated HCl, and crystals of the salt formed spontaneously. These were loosened with the addition of another 10 mL IPA, and then all was diluted by the addition of an equal volume of anhydrous Et2O. The white crystals were separated by filtration, Et2O washed, and air dried to give 14.1 g of 2,N-dimethyl-4,5-methylenedioxyamphetamine hydrochloride (MADAM-6) as a brilliant white powder with a mp of 206-207 °C. Anal. (C12H18ClNO2) C,H.
DOSAGE: greater than 280 mg.
DURATION: unknown.
QUALITATIVE COMMENTS: (with 180 mg) There is a hint of good things there, but nothing more than a hint. At four hours, there is no longer even a hint.
(with 280 mg) I took 150 milligrams, waited an hour for results, which was niente, nada, nothing. Took supplements of 65 milligrams twice, an hour apart. No effect. Yes, we giveth up.
EXTENSIONS AND COMMENTARY: The structure of MADAM-6 was designed to be that of MDMA, with a methyl group attached at what should be a reasonably indifferent position. In fact, that is the genesis of the name. MDMA has been called ADAM, and with a methyl group in the 6-position, MADAM-6 is quite understandable. And the other ortho-position is, using this nomenclature, the 2-position, and with a methyl group there, one would have MADAM-2. I should make a small apology for the choice of numbers. MDMA is a 3,4-methylenedioxy compound, and the least ambiguous numbering scheme would be to lock the methylenedioxy group inescapably at the 3,4-place, letting the other ring position numbers fall where they may. The rules of chemistry ask that if something is really a 3,4,6-orientation it should be renumbered as a 2,4,5-orientation. Let's quietly ignore that request here.
How fascinating it is, that a small methyl group, something that is little more than one more minor bump on the surface of a molecule that is lumpy and bumpy anyway, can so effectively change the action of a compound. A big activity change from a small structure change usually implies that the bump is at a vital point, such as a target of metabolism or a point of critical fit in some receptor site. And since 6-MADAM can be looked upon as 6-bump-MDMA, and since it is at least 3x less potent than MDMA, the implication is that the action of MDMA requires some unbumpiness at this position for its particular action. There are suggestions that the body may want to put a hydroxyl group right there (a 6-hydroxy-dopamine act), and it couldn't if there was a methyl group right there. The isopropylamine side chain may want a certain degree of swing-around freedom, and this would be restricted by a methyl bump right next to it. And there are all kinds of other speculations possible as to why that position should be open.
Anyway, MADAM-6 is not active. And the equally intriguing positional isomer, the easily made MADAM-2, will certainly contribute to these speculations. A quiz for the reader° Will 2,N-dimethyl-3,4-methylenedioxyamphetamine (MADAM-2) be: (1) Of much reduced activity, akin to MADAM-6, or (2) Of potency and action similar to that of MDMA, or (3) Something unexpected and unanticipated? I know only one way of finding out. Make the Schiffs' base between piperonal and cyclohexylamine, treat this with butyl lithium in hexane with some TMEDA present, add some N-methylformanilide, convert the formed benzaldehyde to a nitrostyrene with nitroethane, reduce this with elemental iron to the phenylacetone, reduce this in the presence of methylamine with sodium cyanoborohydride, then taste the result.
#99 MAL; METHALLYLESCALINE; 3,5-DIMETHOXY-4-METHALLYLOXYPHENETHYLAMINE)
SYNTHESIS: To a solution of 5.8 g of homosyringonitrile (see under ESCALINE for its preparation) in 50 mL of acetone containing 100 mg of decyltriethylammonium iodide there was added 7.8 mL methallyl chloride followed by 6.9 g of finely powdered anhydrous K2CO3. The suspension was kept at reflux by a heating mantle, with effective stirring. After 6 h an additional 4.0 mL of methallyl chloride was added, and the refluxing was continued for an additional 36 h. The solvent and excess methallyl chloride was removed under vacuum and the residue was added to 400 mL H2O. This solution was extracted with 3x75 mL CH2Cl2. The extracts were pooled, washed with 2x50 mL 5% NaOH, and the solvent removed to provide a dark brown oil. This was distilled at 120-130 °C at 0.4 mm/Hg to provide 6.1 g of 3,5-dimethoxy-4-methyallyloxyphenylacetonitrile as a lemon-colored viscous oil. Anal. (C14H17NO3) C,H.
A suspension of 4.2 g LAH in 160 mL anhydrous THF under He was stirred, cooled to 0 °C, and treated with 2.95 ml of 100% H2SO4 added dropwise. This was followed by the addition of 6.0 g of 3,5-dimethoxy-4-methallyloxy-phenylacetonitrile dissolved in 10 mL anhydrous THF, at a slow rate with vigorous stirring. The reaction mixture was held at reflux on the steam bath for 0.5 h, brought back to room temperature, and the excess hydride destroyed with IPA. Sufficient 15% NaOH was added to convert the formed solids to a loose, granular texture, and the entire mixture filtered and washed with THF. The filtrate and washings were pooled, the solvent removed under vacuum, and the residue added to 500 mL dilute HCl. This solution was washed with 2x50 mL CH2Cl2, made basic with aqueous NaOH, and extracted with 3x75 mL CH2Cl2. The extracts were pooled, the solvent removed under vacuum, and the residual pale amber oil distilled at 120-130 °C at 0.3 mm/Hg to provide 1.5 g of a white oil. This was dissolved in 8.0 mL of IPA and neutralized with 25 drops of concentrated HCl. The addition of 40 ml of anhydrous Et2O with stirring produced, after a few moments delay, a spontaneous crystallization of 3,5-dimethoxy-4-methallyloxyphenethylamine hydrochloride (MAL) as fine white needles. After standing overnight these were removed by filtration, washed with an IPA/Et2O mixture, then with Et2O, and allowed to air dry to constant weight. The product weighed 1.1 g, and had a mp of 153-154 °C. Anal. (C14H22ClNO3) C,H.
DOSAGE: 40 - 65 mg.
DURATION: 12 - 16 h.
QUALITATIVE COMMENTS: (with 45 mg) Too much overload. I am sur-rounded with unreality. I do not choose to repeat the experiment.
(with 45 mg) I am basically favorably impressed. I believe the initial discomfort would be alleviated by taking two 30 milligram doses separated by an hour.
(with 45 mg) Much too much too much. There are shades of what might become amnesia. I am losing immediate contact. I will not repeat.
(with 50 mg) A good level. I found myself totally caught up in the visual theater. Although I had trouble sleeping, I would willingly repeat the experiment at the same level.
(with 60 mg) Extremely restless. Am very impressed with all the activity. But if I repeated it would be at a lower dose.
(with 60 mg) Friendly territory. There is much kaleidoscopic Tneon' colors. Eyes closed very active. Eyes open there is considerable visual distortions seen in melted wax. Faces are distorted (friendly) but the sinister is not far away.
(with 65 mg) Completely involved Q good psychedelic state Q visual entertainment with alternation (i.e., depth and movement) at the retinal level Q detail in watercolors. Later in the experience (the 8 hour point) easy childhood memory recall.
(with 65 mg) Beautiful. To a +2 by the 1st hr and continued climbing. Intense +3 within 2 hrs. Quite strong body. Diuretic. Fantasy, imagery, erotic. Way up, good connections between parts of self. Slight slowing of pulse in 7th to 8th hour. Excellent solid sleep with strong, clear, balancing dreams. But not until after 12 hrs.
EXTENSIONS AND COMMENTARY: This testimony can be accurately described as a mixed bag°
This base, MAL, lies as a hybrid of two other compounds, AL and CPM. It is an olefin (as is AL) which means that it has a place of unsaturation in its structure. And it is an isostere of CPM which means that the carbon atoms are all in the same location, but just the connecting electrons (called the chemical bonds) are in different places. Actually there is yet a third compound in this same picture, called PROPYNYL. And yet, although all of them have extremely close structural similarities, there are such great differences in action that one does not dare to generalize. CPM leads largely to fantasy, MAL largely to visual imagery, AL is twice as potent as either of these but it doesn't show either effect, and PROPYNYL is almost without any action at all.
Speaking of generalization, I am glad that there are always exceptions. Some years ago, I had a most difficult experience with a strain of marijuana that was known by the name of DRED. The only word that I can use to describe my response to it is to say that I felt I had been poisoned. From this I warned myself to beware (and to believe in) whatever common name a drug might have been given. Fortunately, MAL did not live up to its name (at least for me), although some of the experimental subjects might disagree°
One additional compound was suggested by these parallels. Each of these three drugs can be viewed as having a negative something hanging out a-ways from the molecular center. With AL and MAL, this is the olefin double bond. With CPM this is a very strained three-member ring. What about an oxygen? The reaction between homosyringonitrile and methoxyethyl chloride produced the precursor to such a product (3,5-dimethoxy-4-(2-methoxyethoxy)-phenethylamine) but the yield was so bad that the project was abandoned. This same grouping has successfully been put into the 4-position of the sulfur-containing analog, and the result (2C-T-13) has proved to be quite a potent and interesting material. Maybe someday hang a sulfur atom out there at the end of that chain.
The name methallylescaline actually is completely unsound. There is no union of a methallyl with an escaline. What is really there is not an escaline at all, but rather a mescaline with a 2-propene attached to the methyl of the methoxy on the 4-position. There is no way of naming the thing in that manner, so the only logical solution is to take off the methyl entirely, and then put the methallyl on in its place. The name of this would then be 4-methylallyldesmethylmescaline. That would have received the abbreviation MAD which would have been even more difficult to deal with. MAL is preferable.
#100 MDA; 3,4-METHYLENEDIOXYAMPHETAMINE
SYNTHESIS: (from piperonal) To a solution of 15.0 g piperonal in 80 mL glacial acetic acid there was added 15 mL nitroethane followed by 10 g cyclohexylamine. The mixture was held at steam-bath temperature for 6 h, diluted with 10 mL H2O, seeded with a crystal of product, and cooled overnight at 10 °C. The bright yellow crystals were removed by filtration, and air dried to yield 10.7 g of 1-(3,4-methylenedioxyphenyl)-2-nitropropene with a mp of 93-94 °C. This was raised to 97-98 °C by recrystallization from acetic acid. The more conventional efforts of nitrostyrene synthesis using an excess of nitroethane as a solvent and anhydrous ammonium acetate as the base, gives impure product in very poor yields. The nitrostyrene has been successfully made from the components in cold MeOH, with aqueous NaOH as the base.
A suspension of 20 g LAH in 250 mL anhydrous THF was placed under an inert atmosphere and stirred magnetically. There was added, dropwise, 18 g of 1-(3,4-methylenedioxyphenyl)-2-nitropropene in solution in THF and the reaction mixture was maintained at reflux for 36 h. After being brought back to room temperature, the excess hydride was destroyed with 15 mL IPA, followed by 15 mL of 15% NaOH. An additional 50 mL H2O was added to complete the conversion of the aluminum salts to a loose, white, easily filtered solid. This was removed by filtration, and the filter cake washed with additional THF. The combined filtrate and washes were stripped of solvent under vacuum, and the residue dissolved in dilute H2SO4. Washing with 3x75 mL CH2Cl2 removed much of the color, and the aqueous phase was made basic and reextracted with 3x100 mL CH2Cl2. Removal of the solvent yielded 13.0 g of a yellow-colored oil that was distilled. The fraction boiling at 80-90 °C at 0.2 mm weighed 10.2 g and was water-white. It was dissolved in 60 mL of IPA, neutralization with concentrated HCl, and diluted with 120 mL of anhydrous Et2O which produced a lasting turbidity. Crystals formed spontaneously which were removed by filtration, washed with Et2O, and air dried to provide 10.4 g of 3,4-methylenedioxyamphetamine hydrochloride (MDA) with a mp of 187-188 °C.
(from 3,4-methylenedioxyphenylacetone) To a solution of 32.5 g anhydrous ammonium acetate in 120 mL MeOH, there was added 7.12 g 3,4-methylenedioxyphenylacetone (see under MDMA for its preparation) followed by 2.0 g sodium cyanoborohydride. The resulting yellow solution was vigorously stirred, and concentrated HCl was added periodically to keep the pH of the reaction mixture between 6 and 7 as determined by external damp universal pH paper. After several days, undissolved solids remained in the reaction mixture and no more acid was required. The reaction mixture was added to 600 mL of dilute HCl, and this was washed with 3x100 mL CH2Cl2. The combined washes were back-extracted with a small amount of dilute HCl, the aqueous phases combined, and made basic with 25% NaOH. This was then extracted with 3x100 mL CH2Cl2, these extracts combined, and the solvent removed under vacuum to provide 3.8 g of a red-colored residue. This was distilled at 80-90 °C at 0.2 mm/Hg to provide 2.2 g of an absolutely water-white oil. There was no obvious formation of a carbonate salt when exposed to air. This was dissolved in 15 mL IPA, neutralized with 25 drops of concentrated HCl, and diluted with 30 mL anhydrous Et2O. Slowly there was the deposition of white crystals of 3,4-methylenedioxyamphetamine hydrochloride (MDA) which weighed 2.2 g and had a mp of 187-188 °C. The preparation of the formamide (a precursor to MDMA) and the acetamide (a precursor to MDE) are described under those entries.
DOSAGE: 80 - 160 mg.
DURATION: 8 - 12 h.
QUALITATIVE COMMENTS: (with 100 mg) The coming on was gradual and pleasant, taking from an hour to an hour and one half to do so. The trip was euphoric and intense despite my having been naturally depleted from a working day and having started so late. One thing that impressed itself upon me was the feeling I got of seeing the play of events, of what I thought to be the significance of certain people coming into my life, and why my Tdance', like everyone else's, is unique. I saw that every encounter or event is a potential for growth, and an opportunity for me to realize my completeness at where I am, here and now, not at some future where I must lug the pieces of the past for a final assemblage Tthere.' I was reminded of living the moment to its fullest and I felt that seeing this was indicative that I was on the right track.
(with 128 mg) Forty-five minutes after the second dosage, when I was seated in a room by myself, not smoking, and where there was no possible source of smoke rings, an abundance of curling gray smoke rings was readily observed in the environment whenever a relaxed approach to subjective observation was used. Visually these had complete reality and it seemed quite unneccessary to test their properties because it was surely known and fully appreciated that the source of the visual phenomena could not be external to the body. When I concentrated my attention on the details of the curling gray forms by trying to note how they would be affected by passing a finger through their apparent field, they melted away. Then, when I relaxed again, the smoke rings were there. I was as certain that they were really there as I am now sure that my head is on top of my body.
(with 140 mg) I vomited quite abruptly, and then everything was OK. I had been drinking probably excessively the last two days, and maybe the body needed to unpoison itself. The tactile sense is beautiful, but there seems to be some numbness as well, and I feel that nothing erotic would be do-able. Intimacy, yes, but no performance I'm pretty sure. I saw the experience start drifting away only four hours into it, and I was sad to see it go. It was an all around delightful day.
(with 200 mg, 2x100 mg spaced 1 h) RThe first portion was apparent at one-half hour. There was microscopic nausea shortly after the second portion was taken, and in an hour there was a complete +++ developed. The relaxation was extreme. And there seemed to be time distortion, in that time seemed to pass slowly. There was a occasional LSD-like moment of profoundness, but by and large it was a simple intoxication with most things seeming quite hilarious. The intoxication was also quite extreme. Some food was tried later in the experiment, and it tasted good, but there was absolutely no appetite. None at all.
(with 60 mg of the RRS isomer) There was a light and not too gentle development of a somewhat brittle wound-up state, a + or even a ++. Chills, and I had to get under an electric blanket to be comfortable. The effects smoothed out at the fourth hour, when things started to return to baseline. Not too entertaining.
(with 100 mg of the RRS isomer) Rapid development from the 40 minute point to an hour and a quarter; largely a pleasant intoxication, but there is something serious there too. No great insights, and not too much interference with the day's goings-on. Completely clear at the 8 hour point.
(with 120 mg of the RRS isomer) This is a stoning intoxicant. I would not choose to drive, because of possible judgement problems, but my handwriting seems to be clear and normal. The mental excitement dropped rapidly but I was aware of physical residues for several additional hours.
(with 80 mg of the RSS isomer) A very thin, light threshold, which is quite delightful. I am quite willing to push this a bit higher.
(with 120 mg of the RSS isomer) Perhaps to a one +. Very light, and very much like MDMA, but perhaps shorter lived. I am pretty much baseline in three hours.
(with 160 mg of the RSS isomer) The development is very rapid, and there is both muscular tremor and some nausea. The physicals are quite bothersome. With eyes closed, there are no effects noticeable, but with eyes open, things are quite bright and sparkling. The muscular spasms persist, and there is considerable teeth clenching. I feel that the mental is not worth the physical.
EXTENSIONS AND COMMENTARY: There are about twenty different synthetic routes in the literature for the preparation of MDA. Many start with piperonal, and employ it to make methylenedioxyphenylacetone or a methylenedioxydihydro-cinnamic acid amide instead of the nitrostyrene. The phenylacetone can be reduced in several ways other than the cyanoborohydride method mentioned here, and the amide can be rearranged directly to MDA. And there are additional methods for the reduction of the nitrostyrene that use no lithium aluminum hydride. Also there are procedures that have safrole or isosafrole as starting points. There is even one in the underground literature that starts with sassafras root bark. In fact, it is because safrole is one of the ten essential oils that MDA can humorously be referred to as one of the Ten Essential Amphetamines. See the comments under TMA.
There is a broad and checkered history concerning the use and abuse of MDA, and it is not the case that all the use was medical and all the abuse was social. One of the compulsive drives of both the military and the intelligence groups, just after World War II, was to discover and develop chemical agents which might serve as "truth serums" or as incapacitating agents. These government agencies considered the area of the psychedelics to be a fertile field for searching. The giving of relatively unexplored drugs in a cavalier manner to knowing and unknowing subjects was commonplace. There was one case in 1953, involving MDA and a psychiatric patient named Howard Blauer that proved fatal. The army had contracted with several physicians at the New York State Psychiatric Institute to explore new chemicals from the Edgewood Arsenal and one of these, with a chemical warfare code number of EA-1298, was MDA. The last and lethal injection into Blauer was an intravenous dose of 500 milligrams.
There have been a number of medical explorations. Under the code SKF-5 (and trade name of Amphedoxamine) it was explored as an anorexic agent. It has been found promising in the treatment of psychoneurotic depression. There are several medical reports, and one book (Claudio Naranjo's The Healing Journey), that describe its values in psychotherapy.
MDA was also one of the major drugs that was being popularly used in the late 1960's when the psychedelic concept exploded on the public scene. MDA was called the "hug-drug" and was said to stand for Mellow Drug of America. There was no difficulty in obtaining unending quantities of it, as it was available as a research chemical from several scientific supply houses (as were mescaline and LSD) and was sold inexpensively under its chemical name.
A few experimental trials with the pure optical isomers show a consistency with all the other psychedelic compounds that have been studied in their separated forms, the higher potency with the RRS isomer. The less potent RSS isomer seemed to be more peaceful and MDMA-like at lower doses, but there were worrisome toxic signs at higher levels.
The structure of MDA can be viewed as an aromatic ring (the 3,4-methylenedioxyphenyl ring) with a three carbon chain sticking out from it. The amine group is on the second of the three carbon atoms. The isomers, with the amine function moved to the first of these carbons atoms (a benzylamine) and with the amine function moved to the third (furthest out atom) of these carbon atoms (a (n)-propylamine), are known and both have been assayed.
The benzylamine counterpart (as if one were to move the amine function from the beta-carbon to the alpha-carbon of the three carbon chain of the amphetamine molecule) is alpha-ethyl-3,4-methylenedioxybenzylamine or 1-amino-1-(3,4-methylenedioxyphenyl)propane, ALPHA. The hydrochloride salt has a mp of 199-201 °C. At low threshold levels (10 milligram area) there were eyes-closed "dreams" with some body tingling. The compound was not anorexic at any dose (up to 140 milligrams) and was reported to produce a pleasant, positive feeling. It is very short-lived (about 3 hours). The N-methyl homologue is alpha-ethyl-N-methyl-3,4-methylenedioxybenzylamine or 1-methylamino-1-(3,4-methylenedioxy-phenyl)propane, M-ALPHA. It is similar in action, but is perhaps twice as potent (a plus one or plus two dose is 60 milligrams) and of twice the duration.
The (n)-propylamine counterpart (as if one were to move the amine function the other direction, from the beta-carbon to the gamma-carbon of the three carbon chain of the amphetamine molecule) is gamma-3,4-methylenedioxyphenylpropylamine or 1-amino-3-(3,4-methylenedioxyphenyl)propane, GAMMA. The hydrochloride salt has a mp of 204-205 °C. At oral levels of 200 milligrams there was some physical ill-at-ease, possible time distortion, and a feeling of being keenly aware of one's surroundings. The duration of effects was 4 hrs.
The phenethylamine that corresponds to MDA (removing the alpha-methyl group) is 3,4-methylenedioxyphenethylamine, or homopiperonylamine, or MDPEA, or simply H in the vocabulary of the Muni-Metro world. This compound is an entry in its own rights. The adding of another carbon atom to the alpha-methyl group of MDA gives compound J, and leads to the rest of the Muni-Metro series (K, L etc). All of this is explained under METHYL-J. The bending of this alpha-methyl group back to the aromatic ring gives an aminoindane, and with J one gets an aminotetralin. Both compounds react in animal discrimination studies identically to MDMA, and they appear to be free of neurochemical toxicity.
The two possible homologues, with either one or two methyl groups on the methylene carbon of the methylenedioxy group of MDA, are also known. The ethylidene compound (the acetaldehyde addition to the catechol group) has been encoded as EDA, and the acetone (isopropylidine addition to the catechol group) is called IDA. In animal discrimination studies, and in in vitro neurotransmitter studies, they both seem to be of decreased potency. EDA is down two to three-fold from MDA, and IDA is down by a factor of two to three-fold again. Human trials of up to 150 milligrams of the hydrochloride salt of EDA producd at best a threshold light-headedness. IDA remains untested as of the present time. The homologue of MDA (actually of MDMA) with the added carbon atom in, rather than on, the methylenedioxy ring, is a separate entry; see MDMC.
A final isomer to be mentioned is a positional isomer. The 3,4-methylene-dioxy group could be at the 2,3-position of the amphetamine skeleton, giving 2,3-methylenedioxyamphetamine, or ORTHO-MDA. It appears to be a stimulant rather than another MDA. At 50 milligrams, one person was awake and alert all night, but reported no MDA-like effects.
#101 MDAL; N-ALLYL-MDA; 3,4-METHYLENEDIOXY-N- ALLYLAMPHETAMINE
SYNTHESIS: A total of about 20 mL allylamine was introduced under the surface of 20 mL concentrated HCl, and the mixture stripped of volatiles under vacuum The resulting 24 g of wet material did not yield any crystals with either acetone or Et2O. This was dissolved in 75 mL MeOH, treated with 4.45 g 3,4-methylenedioxy-phenylacetone (see under MDMA for its preparation), and finally with 1.1 g sodium cyanoborohydride. Concentrated HCl was added as needed over the course of 5 days to keep the pH constant at about 6. The reaction mixture was then added to a large amount of H2O, acidified with HCl, and extracted with 3x100 mL CH2Cl2. The aqueous phase was made basic with 25% NaOH, and extracted with 3x100 mL CH2Cl2. Evaporation of the solvent from these extracts yielded 3.6 g of an amber oil which, on distillation at 90-95 °C at 0.2 mm/Hg, yielded 2.6 g of an off-white oil. This was dissolved in 10 mL IPA, neutralized with about 25 drops of concentrated HCl, and the resulting clear but viscous solution was diluted with Et2O until crystals formed. These were removed by filtration, washed with IPA/Et2O (1:1), then with Et2O, and air dried to constant weight. There was thus obtained 2.5 g of 3,4-methylenedioxy-N-allylamphetamine hydrochloride (MDAL) with a mp of 174-176 °C and a proton NMR spectrum that showed that the allyl group was intact. Anal. (C13H18ClNO2) N.
DOSAGE: greater than 180 mg.
DURATION: unknown.
EXTENSIONS AND COMMENTARY: Here is another inactive probe, like MDPR, that could possibly serve as a primer to LSD. The three carbon chain on the nitrogen seen with MDPR is almost identical to the three carbon chain on the nitrogen atom of MDAL. And yet, where an "inactive" level of 180 milligrams of MDPR is a rather fantastic enhancer of LSD action, the same weight of this compound not only does not enhance, but actually seems to somewhat antagonize the action of LSD. All this difference from just a couple of hydrogen atoms. Identical carbon atoms, identical oxygen atoms, and an identical nitrogen atom. And all in identical places. Simply C13H18ClNO2 rather than C13H20ClNO2.
So, apparently, almost identical is not good enough°
#102 MDBU; N-BUTYL-MDA; 3,4-METHYLENEDIOXY-N-BUTYLAMPHETAMINE
SYNTHESIS: A total of 30 mL butylamine was introduced under the surface of 33 mL concentrated HCl, and the mixture stripped of volatiles under vacuum. The resulting glassy solid was dissolved in 160 mL MeOH and treated with 7.2 g 3,4-methylenedioxyphenylacetone (see under MDMA for its preparation). To this there was added 50% NaOH dropwise until the pH was at about 6 as determined by the use of external dampened universal pH paper. The solution was vigorously stirred and 2.8 g sodium cyanoborohydride was added. Concentrated HCl was added as needed, to keep the pH constant at about 6. The addition required about two days, during which time the reaction mixture first became quite cottage-cheese like, and then finally thinned out again. All was dumped into 1 L H2O acidified with HCl, and extracted with 3x100 mL CH2Cl2. These extracts were combined, extracted with 2x100 mL dilute H2SO4, which was combined with the aqueous fraction above. This latter mixture was made basic with 25% NaOH, and extracted with 3x150 mL CH2Cl2. Evaporation of the solvent yielded 4.0 g of an amber oil which, on distillation at 90-100 °C at 0.15 mm/Hg, yielded 3.2 g of a white clear oil. This was dissolved in 20 mL IPA, neutralized with 30 drops of concentrated HCl, and the spontaneously formed crystals were diluted with sufficient anhydrous Et2O to allow easy filtration. After Et2O washing and air drying, there was obtained 2.8 g of 3,4-methylenedioxy-N-butylamphetamine hydrochloride (MDBU) as white crystals with a mp of 200-200.5 °C. Anal. (C14H22ClNO2) N.
DOSAGE: greater than 40 mg.
DURATION: unknown.
EXTENSIONS AND COMMENTARY: Straight chain homologues on the nitrogen atom of MDA longer than two carbons are probably not active. This butyl compound provoked no interest, and although the longer chain counterparts were made by the general sodium cyanoborohydride method (see under MDBZ), they were not tasted. All mouse assays that compared this homologous series showed a consistent decrease in action (anesthetic potency and motor activity) as the alkyl chain on the nitrogen atoms was lengthened.
This synthetic procedure, using the hydrochloride salt of the amine and sodium cyanoborohydride in methanol, seems to be quite general for ketone compounds related to 3,4-methylenedioxyphenylacetone. Not only were most of the MD-group of compounds discussed here made in this manner, but the use of phenylacetone (phenyl-2-propanone, P-2-P) itself appears to be equally effective. The reaction of butylamine hydrochloride in methanol, with phenyl-2-propanone and sodium cyanoborohydride at pH of 6, after distillation at 70-75 °C at 0.3 mm/Hg, produced N-butylamphetamine hydrochloride (23.4 g from 16.3 g P-2-P). And, in the same manner with ethylamine hydrochloride there was produced N-ethylamphetamine (22.4 g from 22.1 g P-2-P) and with methylamine hydrochloride there was produced N-methylamphetamine hydrochloride (24.6 g from 26.8 g P-2-P). The reaction with simple ammonia (as ammonium acetate) gives consistently poor yields in these reactions.
#103 MDBZ; N-BENZYL-MDA; 3,4-METHYLENEDIOXY-N-BENZYLAMPHETAMINE
SYNTHESIS: To a suspension of 18.6 g benzylamine hydrochloride in 50 mL warm MeOH there was added 2.4 g of 3,4-methylenedioxyphenylacetone (see under MDMA for its preparation) followed by 1.0 g sodium cyanoborohydride. Concentrated HCl in MeOH was added over several days as required to maintain the pH at about 6 as determined with external, dampened universal paper. When the demand for acid ceased, the reaction mixture was added to 400 mL H2O and made strongly acidic with an excess of HCl. This was extracted with 3x150 mL CH2Cl2 (these extracts must be saved as they contain the product) and the residual aqueous phase made basic with 25% NaOH and again extracted with 4x100 mL CH2Cl2. Removal of the solvent under vacuum and distillation of the 8.7 g pale yellow residue at slightly reduced pressure provided a colorless oil that was pure, recovered benzylamine. It was best characterized as its HCl salt (2 g in 10 mL IPA neutralized with about 25 drops concentrated HCl, and dilution with anhydrous Et2O gave beautiful white crystals, mp 267-268 °C). The saved CH2Cl2 fractions above were extracted with 3x100 mL dillute H2SO4. These pooled extracts were back-washed once with CH2Cl2, made basic with 25% NaOH, and extracted with 3x50 mL CH2Cl2. The solvent was removed from the pooled extracts under vacuum, leaving a residue of about 0.5 g of an amber oil. This was dissolved in 10 mL IPA, neutralized with concentrated HCl (about 5 drops) and diluted with 80 mL anhydrous Et2O. After a few min, 3,4-methylenedioxy-N-benzylamphetamine hydrochloride (MDBZ) began to appear as a fine white crystalline product. After removal by filtration, Et2O washing and air drying, this weighed 0.55 g, and had a mp of 170-171 °C with prior shrinking at 165 °C. Anal. (C17H20ClNO2) N.
DOSAGE: greater than 150 mg.
DURATION: unknown.
EXTENSIONS AND COMMENTARY: The benzyl group is a good ally in the synthetic world of the organic chemist, in that it can be easily removed by catalytic hydrogenation. This is a trick often used to protect (for a step or series of steps) a position on the molecule, and allowing it to become free and available at a later part in a synthetic scheme. In pharmacology, however, it is often a disappointment. With most centrally active alkaloids, there is a two-carbon separation between the weak base that is called the aromatic ring, and the strong base that is called the nitrogen. This is what makes phenethylamines what they are. The phen- is the aromatic ring (this is a shortened form of prefix phenyl which is a word which came, in turn, from the simplest aromatic alcohol, phenol); the ethyl is the two carbon chain, and the amine is the basic nitrogen. If one carbon is removed, one has a benzylamine, and it is usually identified with an entirely different pharmacology, or is most often simply not active. A vivid example is the narcotic drug, Fentanyl. The replacement of the phenethyl group, attached to the nitrogen atom with a benzyl group, virtually eliminates its analgesic potency.
Here too, there appears to be little if any activity in the N-benzyl analogue of MDA. A number of other variations had been synthesized, and none of them ever put into clinical trial. With many of them there was an ongoing problem in the separation of the starting amine from the product amine. Sometimes the difference in boiling points could serve, and sometimes their relative polarities could be exploited. Sometimes, ion-pair extraction would work wonders. But occasionally, nothing really worked well, and the final product had to be purified by careful crystallization.
Several additional N-homologues and analogues of MDA are noted here. The highest alkyl group on the nitrogen of MDA to give a compound that had been assayed, was the straight-chain butyl homologue, MDBU. Six other N-alkyls were made, or attempted. Isobutylamine hydrochloride and 3,4-methylenedioxyphenylacetone were reduced with sodium cyanoborohydride in methanol to give 3,4-methylenedioxy-N-(i)-butylamphetamine boiling at 95-105 °C at 0.15 mm/Hg and giving a hydrochloride salt (MDIB) with a mp of 179-180 °C. Anal. (C14H22ClNO2) N. The reduction with sodium cyanoborohydride of a mixture of (t)-butylamine hydrochloride and 3,4-methylenedioxyphenylacetone in methanol produced 3,4-methylenedioxy-N-(t)-butylamphetamine (MDTB) but the yield was miniscule. The amyl analog was similarly prepared from (n)-amylamine hydrochloride and 3,4-methylenedioxyphenylacetone in methanol to give 3,4-methylenedioxy-N-amylamphetamine which distilled at 110-120 °C at 0.2 mm/Hg and formed a hydrochloride salt (MDAM) with a mp of 164-166 °C. Anal. (C15H24ClNO2) N. A similar reaction with (n)-hexylamine hydrochloride and 3,4-methylenedioxyphenylacetone in methanol, with sodium cyanoborohydride, produced after acidification with dilute sulfuric acid copious white crystals that were water and ether insoluble, but soluble in methylene chloride° This sulfate salt in methylene chloride was extracted with aqueous sodium hydroxide and the remaining organic solvent removed to give a residue that distilled at 110-115 °C at 0.2 mm/Hg to give 3,4-methylenedioxy-N-(n)-hexylamphetamine which, as the hydrochloride salt (MDHE) had a mp of 188-189 °C. Anal. (C16H26ClNO2) N. An attempt to make the 4-amino-heptane analogue from the primary amine, 3,4-methylenedioxyphenylacetone, and sodiumcyanoborohydride in methanol seemed to progress smoothly, but none of the desired product 3,4-methylenedioxy-N-(4-heptyl)-amphetamine could be isolated. This base has been named MDSE, with a SE for septyl rather than HE for heptyl, to resolve any ambiguities about the use of HE for hexyl. In retrospect, it had been assumed that the sulfate salt would have extracted into methylene chloride, and the extraordinary partitioning of the sulfate salt of MDHE mentioned above makes it likely that the sulfate salt of MDSE went down the sink with the organic extracts of the sulfuric acid acidified crude product. Next time maybe ether as a solvent, or citric acid as an acid. With (n)-octylamine hydrochloride and 3,4-methylenedioxyphenylacetone in methanol, with sodium cyanoborohydride, there was obtained 3,4-methylenedioxy-N-(n)-octylamphetamine as a water-insoluble, ether-insoluble sulfate salt. This salt was, however, easily soluble in methylene chloride, and with base washing of this solution, removal of the solvent, and distillation of the residue (130-135 °C at 0.2 mm/Hg) there was eventually gotten a fine hydrochloride salt (MDOC) as white crystals with a mp of 206-208 °C. Anal. (C18H30ClNO2) N.
As to N,N-dialkylhomologues of MDA, the N,N-dimethyl has been separately entered in the recipe for MDDM. Two efforts were made to prepare the N,N-diethyl homologue of MDA. The reasonable approach of reducing a mixture of diethylamine hydrochloride and 3,4-methylenedioxyphenylacetone in methanol with sodium cyanoborohydride was hopelessly slow and gave little product. The reversal of the functionality was successful. Treatment of MDA (as the amine) and an excess of acetaldehyde (as the carbonyl source) with sodium borohydride in a cooled acidic medium gave, after acid-base workup, a fluid oil that distilled at 85-90 °C at 0.15 mm/Hg and was converted in isopropanol with concentrated hydrochloric acid to 3,4-methylenedioxy-N,N-diethylamphetamine (MDDE) with a mp of 177-178 °C. Anal. (C14H22ClNO2) N.
And two weird N-substituted things were made. Aminoacetonitrile sulfate and 3,4-methylenedioxyphenylacetone were reduced in methanol with sodium cyanoborohydride to form 3,4-methylenedioxy-N-cyanomethylamphetamine which distilled at about 160 °C at 0.3 mm/Hg and formed a hydrochloride salt (MDCM) with a mp of 156-158 °C after recrystallization from boiling isopropanol. Anal. (C12H15ClN2O2) N. During the synthesis of MDCM, there appeared to have been generated appreciable ammonia, and the distillation provided a fore-run that contained MDA. The desired product had an acceptable NMR, with the N-cyanomethylene protons as a singlet at 4.38 ppm. A solution of t-butylhydrazine hydrochloride and 3,4-methylenedioxyphenylacetone in methanol was reduced with sodium cyanoborohydride and gave, after acid-basing and distillation at 95-105 °C at 0.10 mm/Hg, a viscous amber oil which was neutralized in isopropanol with concentrated hydrochloric acid to provide 3,4-methylenedioxy-N-(t)-butylaminoamphetamine hydrochloride (MDBA) with a mp of 220-222 °C with decomposition. Anal. (C14H23ClN2O2); N: calcd, 9.77; found, 10.67, 10.84.
#104 MDCPM; CYCLOPROPYLMETHYL-MDA; 3,4-METHYLENEDIOXY-N-CYCLOPROPYLMETHYLAMPHETAMINE
SYNTHESIS: A solution of 9.4 g cyclopropylmethylamine hydrochloride in 30 mL MeOH was treated with 1.8 g 3,4-methylenedioxyphenylacetone (see under MDMA for its preparation) followed by 0.5 g sodium cyanoborohydride. Concentrated HCl was added as needed to keep the pH constant at about 6. After several days stirring, the reaction mixture was added to H2O, acidified with HCl, and washed with 2x100 mL CH2Cl2. The aqueous phase was made basic with 25% NaOH, and extracted with 3x150 mL CH2Cl2. Removal of the solvent from these extracts under vacuum yielded 2.8 g of a crude product which, on distillation at 90-100 °C at 0.1 mm/Hg, yielded 0.4 g of a clear white oil. This was dissolved in a small amount of IPA, neutralized with a few drops of concentrated HCl, and diluted with anhydrous Et2O to the point of turbidity. There was obtained a small yield of crystalline 3,4-methylenedioxy-N-cyclopropylmethylamphetamine hydrochloride (MDCPM) which was filtered off, Et2O washed and air dried. The mp was 218-220 °C, with extensive darkening just prior to melting. Anal. (C14H20ClNO2) N.
DOSAGE: greater than 10 mg.
DURATION: unknown.
EXTENSIONS AND COMMENTARY: The record of the tasting assay of this compound is pretty embarrassing. The highest level tried was 10 milligrams, which showed no hint of activity. But in light of the rather colorful activities of other cyclopropylmethyl things such as CPM and 2C-T-8 , this compound might someday warrant reinvestigation. It is a certainty that the yield could only be improved with a careful resynthesis.
#105 MDDM; N,N-DIMETHYL-MDA; 3,4-METHYLENEDIOXY-N,N-DIMETHYLAMPHETAMINE
SYNTHESIS: To a well stirred solution of 9.7 g dimethylamine hydrochloride in 50 mL MeOH there was added 3.56 g of 3,4-methylenedioxyphenylacetone (see under MDMA for its preparation) followed by 0.88 g sodium cyanoborohydride. A 1:1 mixture of concentrated HCl and MeOH was added as required to maintain the pH at about 6 as determined with external, dampened universal paper. Twenty drops were called for over the first four h, and a total of 60 drops were added over the course of two days at which time the reduction was complete. After the evaporation of most of the MeOH solvent, the reaction mixture was added to 250 mL H2O and made strongly acidic with an excess of HCl. After washing with 2x100 mL CH2Cl2 the aqueous phase was made basic with 25% NaOH, and extracted with 3x100 mL CH2Cl2. Removal of the solvent under vacuum yielded a nearly colorless oil that was distilled at 85-90 °C at 0.3 mm/Hg. There was obtained 1.5 g of a water-white oil that was dissolved in 8 mL IPA, neutralized with concentrated HCl and then diluted with 10 mL anhydrous Et2O. The slightly turbid solution deposited a light lower oily layer which slowly crystallized on scratching. With patience, an additional 75 mL of Et2O was added, allowing the formation of a white crystalline mass. This was removed by filtration and washed with additional Et2O. After air drying there was obtained 1.3 g of 3,4-methylenedioxy-N,N-dimethylamphetamine hydrochloride (MDDM) with a mp of 172-173 °C. The NMR spectrum (60 mH) of the hydrochloride salt (in D2O and with external TMS) was completely compatible with the expected structure. The signals were: 1.25, 1.37 (d) CCH3, 3H; ArCH2 under the N(CH3)2, 2.96, 8H; CH (m) 3.65; CH2O2 (s) 6.03 2H; ArH 6.93 (3H). Anal: (C12H18ClNO2) N.
DOSAGE: greater than 150 mg.
DURATION: unknown.
QUALITATIVE COMMENTS: (with 150 mg) No effects whatsoever.
(with 150 mg) The effects, if any, were so-so. Perhaps a threshold. But my libido was non-existent for three days.
(with 550 mg) I took 550 milligrams of it Saturday night and I had a pretty bad trip. On a scale of positive 10 to negative 10 it was about a negative 6. It really downed me. Two other friends took 200 milligrams. They found it very pleasant after about 20 minutes. It was a plus 3 [on the -10 to +10 scale]. Then it wore off a little bit; and then, 4 hours later, it hit them even stronger and was about a plus 5.
(with 1000 mg) I took up to a gram of it and absolutely nothing.
EXTENSIONS AND COMMENTARY: I cannot attest for the actual drug that had been used in the two larger-dose reports above. These are from an anonymous source associated with clandestine syntheses. If this material does eventually prove to be active, it is going to require a pretty hefty dose. But it may well have some activity, as there have been reports in the forensic literature of its preparation, or at least its intended preparation, in illicit laboratories. It seems unlikely that much effort would be directed towards the synthesis of a completely inactive compound.
The reduced potency of MDDM has been exploited in an unexpected way. Based on the premise that the dialkylation of the amine group of amphetamine makes the parent compound intrinsically less active but without interfering with its ability to enter the brain, a large number of materials have been explored to take advantage of this very property. There is a need in medical diagnosis for agents that can allow various organs of the body to be visualized. One of the most powerful modalities for this work is the positron camera, and the use of the unusual properties of the positron that allow it to work. In the art of positron emission tomography (PET), an emitted positron (from a radioactive and thus unstable atom) will quickly interact with a nearby electron and all mass disappears with the complete conversion to energy. The detection of the produced pair of annihilation gamma rays will establish with great exactness the line along which this interaction occurred. So if one were to put an unstable atom into a compound that went to the tissue of the brain, and this atom were to decay there, the resulting gamma rays would allow a "photograph" to be made of the brain tissue. One could in this way visualize brain tissue, and observe abnormalities.
But what is needed is a molecule that carries the unstable atom (and specifically one that emits positrons) and one which goes to the brain as well. One of the very best unstable atoms for the formation of positrons is iodine, where there is an isotope of mass 122 which is perfect for these needs. And, of course, the world of the psychedelic drugs is tailor-made to provide compounds that go to the brain. But, the last thing that the physician wants, with the diagnostic use of such tools, would be to have the patient bouncing around in some turned-on altered state of consciousness.
So the completely logical union of these requirements is to take a compound such as DOI (carrying the needed atom and certainly going to the brain) and put two methyl groups on the nitrogen (which should reduce the chances for conspicuous biological activity). This compound was made, and it does label the brain, and it has shown promise as a flow indicator in the brain, and it and several of its close relatives are discussed in their own separate recipe, called IDNNA.
